
PFT Machine: A Complete Guide to Pulmonary Function Testing, Spirometry, and Lung Function Tests
Pulmonary function testing is an essential part of respiratory assessment, providing objective information about how effectively the lungs move air, maintain adequate lung volumes, and facilitate the exchange of oxygen and carbon dioxide. In clinical practice, a PFT machine is used to evaluate different aspects of respiratory function through specialized tests that measure airflow, lung capacity, and the ability of gases to pass between the lungs and bloodstream. These assessments help healthcare professionals identify abnormalities in breathing patterns, investigate persistent respiratory symptoms, and evaluate conditions that interfere with normal lung function. They are particularly valuable when assessing patients with asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, emphysema, and other conditions that affect the airways or lung tissue.
A PFT machine supports this assessment by recording physiological measurements obtained during controlled breathing maneuvers and specialized respiratory procedures. Depending on its design and capabilities, the equipment may perform basic spirometry or more advanced pulmonary function tests involving lung volume measurement, body plethysmography, and diffusion capacity assessment. For example, spirometry measures how much air a person can inhale and exhale and how quickly air can be expelled from the lungs. Measurements such as forced vital capacity (FVC) and forced expiratory volume in one second (FEV1) help identify patterns of airflow limitation, while lung volume and diffusion assessments provide additional information about the amount of air retained in the lungs and the efficiency of gas exchange.
The information obtained from pulmonary function testing is important because different respiratory conditions can produce similar symptoms while affecting the lungs in different ways. A patient experiencing shortness of breath, persistent coughing, wheezing, or reduced exercise tolerance may require pulmonary function tests to determine whether the underlying problem involves airway obstruction, reduced lung expansion, or impaired gas transfer. For instance, asthma and COPD commonly produce obstructive patterns characterized by reduced expiratory airflow, although their clinical features and underlying mechanisms differ. Restrictive conditions, such as pulmonary fibrosis, may instead reduce the amount of air the lungs can hold. Additional assessments, including lung volume testing and DLCO testing, help clarify these abnormalities and provide a more complete picture of respiratory function.
The clinical value of a PFT machine extends beyond the initial assessment of respiratory symptoms. Repeated pulmonary function testing allows healthcare providers to compare current measurements with previous results and identify meaningful changes in respiratory performance. This is particularly important for patients living with chronic respiratory diseases, individuals receiving treatments that may affect lung function, and those requiring regular evaluation of their respiratory status. For example, a patient with COPD may undergo periodic spirometry to monitor airflow limitation and assess changes following treatment, while a patient with suspected pulmonary fibrosis may require lung volume and diffusion assessments to evaluate changes in lung capacity and gas transfer. These measurements provide useful physiological evidence for evaluating treatment response and planning further clinical investigations.
Accurate pulmonary function testing also depends on appropriate equipment operation, patient cooperation, and adherence to standardized testing procedures. During spirometry, for instance, the patient must follow specific breathing instructions, maintain a proper seal around the mouthpiece, inhale fully, and exhale forcefully when instructed. Poor technique, inadequate effort, air leakage, or inconsistent testing conditions can affect measurement quality and make the results difficult to interpret. Healthcare professionals involved in respiratory assessment therefore need to understand the purpose of each procedure, recognize factors that may influence test accuracy, and ensure that the equipment is appropriately maintained. Standardized procedures and quality-control measures help improve the reliability and consistency of pulmonary function measurements.
In nursing and broader healthcare practice, knowledge of pulmonary function testing supports effective patient preparation, safe procedure assistance, and appropriate communication with respiratory therapists and other healthcare professionals. Nurses may help explain testing instructions, review relevant patient history, identify potential difficulties with breathing maneuvers, monitor patients during testing, and reinforce the importance of following preparation guidelines. They should also understand that pulmonary function test results describe patterns of physiological impairment rather than independently confirming every respiratory diagnosis. For example, an obstructive pattern may indicate airflow limitation, but additional clinical information is needed to determine whether the underlying condition is asthma, COPD, or another airway disorder. Integrating test findings with symptoms, physical examination, medical history, and other investigations is therefore essential to appropriate clinical decision-making.
This guide examines the principles and clinical applications of the PFT machine, beginning with its definition, purpose, operating mechanism, and main components. It explores the different types of equipment, including spirometers, portable PFT machines, full pulmonary function testing systems, and body plethysmography machines. It also discusses the major pulmonary function tests performed using this equipment, their applications in assessing respiratory diseases, and the procedures involved in preparing patients and conducting the tests. Further sections explain how to interpret important measurements such as FEV1, FVC, lung volumes, and diffusion capacity, alongside the essential considerations involved in selecting, calibrating, cleaning, and maintaining PFT equipment. Together, these topics provide a foundation for understanding how pulmonary function testing contributes to respiratory assessment, disease monitoring, and the delivery of effective patient care.
Understanding the PFT Machine
A PFT machine is an important diagnostic instrument in respiratory medicine because it provides measurable information about how the lungs and respiratory system function. Unlike a physical examination, which relies on observable signs such as chest movement, breathing rate, wheezing, and respiratory effort, pulmonary function testing provides numerical measurements that help healthcare professionals evaluate airflow, lung capacity, and gas exchange. These measurements are useful when investigating breathing problems, assessing suspected lung conditions, and monitoring patients with established respiratory diseases. Depending on the equipment used, a PFT machine can perform basic spirometry or more advanced assessments involving lung volume measurements, plethysmography, and diffusion capacity testing.
Understanding this equipment involves more than recognizing its appearance or knowing how to operate it. Healthcare professionals need to understand the physiological principles behind the measurements, the different tests the machine can perform, and how the resulting information relates to normal and abnormal respiratory function. This knowledge is particularly important because different pulmonary function tests evaluate different aspects of the respiratory system. For example, spirometry assesses the amount and speed of air a person can exhale, while body plethysmography measures lung volumes that cannot be determined through basic spirometry alone. Similarly, DLCO testing evaluates how effectively gases move from the alveoli into the bloodstream. Together, these assessments provide a broader understanding of respiratory performance.
Definition and Purpose of a Pulmonary Function Testing Machine
A pulmonary function testing machine, commonly called a PFT machine, is a medical diagnostic device designed to measure and evaluate the functional capacity of the lungs and respiratory system. It records physiological changes that occur during breathing and converts them into measurable values that healthcare professionals use to assess lung function. Depending on its configuration, the equipment may measure airflow, the volume of air inhaled and exhaled, total lung capacity, residual volume, and the ability of the lungs to transfer gases into the bloodstream.
The term PFT machine generally refers to equipment used to conduct one or more pulmonary function tests. Some devices are designed primarily for spirometry, whereas more advanced systems combine several testing technologies in one unit. A basic spirometer, for instance, measures the volume and flow of air during breathing maneuvers, while a comprehensive pulmonary function testing machine may also include equipment for lung volume assessment, body plethysmography, and diffusion capacity testing. Therefore, not every spirometer performs every type of pulmonary function test.
The primary purpose of a PFT machine is to provide objective measurements of respiratory function. These measurements help healthcare providers determine whether the respiratory system is functioning within expected limits or whether abnormalities suggest an underlying problem. The equipment is particularly useful when symptoms or clinical findings indicate that a patient may have an obstructive or restrictive lung condition.
The major purposes of a PFT machine include:
1. Assessing airflow and respiratory mechanics: The machine measures how quickly and effectively a person can move air into and out of the lungs. Spirometry provides important measurements such as forced vital capacity (FVC) and forced expiratory volume in one second (FEV1), which help identify airflow obstruction. These values are particularly useful when evaluating patients with suspected asthma, COPD, or other conditions that affect the airways.
2. Measuring lung capacity and volume: Certain pulmonary function tests determine how much air the lungs can hold after different breathing maneuvers. These measurements help identify reduced lung expansion, air trapping, and other abnormalities that may not be apparent through basic spirometry. For example, a patient with pulmonary fibrosis may have reduced total lung capacity because scarring and stiffness of the lung tissue restrict expansion.
3. Evaluating gas exchange and diffusion: Specialized equipment performs DLCO testing to assess how effectively gases pass from the alveoli into the pulmonary capillary blood. The test commonly uses a small, controlled concentration of carbon monoxide to estimate the lungs’ diffusion capacity. Reduced diffusion capacity may occur in conditions such as emphysema, pulmonary fibrosis, and certain pulmonary vascular disorders.
4. Supporting the assessment of respiratory diseases: Pulmonary function testing helps investigate conditions that affect the airways, lung tissue, and respiratory mechanics. Results can provide evidence of obstructive or restrictive patterns, helping healthcare professionals determine which additional investigations may be necessary.
5. Monitoring disease progression and treatment response: Repeated measurements allow healthcare providers to compare a patient’s current respiratory function with previous results. For example, spirometry may be repeated in a patient with asthma to assess changes in airflow following bronchodilator treatment or during ongoing disease management.
6. Establishing baseline respiratory function: A PFT machine can be used to document lung function before certain medical procedures, treatments, or occupational exposures that may affect the respiratory system. Baseline measurements provide a reference for evaluating subsequent changes.
It is important to understand that a PFT machine does not independently diagnose every respiratory disease. Instead, it provides physiological measurements that must be interpreted alongside symptoms, medical history, physical examination findings, and other diagnostic investigations. For example, reduced FEV1 may indicate impaired expiratory airflow, but the healthcare provider must consider the FEV1/FVC ratio, clinical presentation, and other findings to determine whether the abnormality is consistent with COPD, asthma, or another respiratory condition.
Example: Consider a patient who reports persistent shortness of breath, wheezing, and coughing, particularly during physical activity. A healthcare provider may order spirometry using a PFT machine to assess airflow. If the test demonstrates a reduced FEV1/FVC ratio, it may indicate an obstructive ventilatory pattern. The provider may then request additional testing, including a bronchodilator response assessment, to investigate whether the airflow limitation improves after medication. If further evaluation is necessary, lung volume and diffusion capacity measurements may provide additional information about the patient’s respiratory function.
How a PFT Machine Works
A PFT machine works by measuring changes in airflow, pressure, gas concentration, and lung volume during controlled breathing maneuvers. Although the exact operating mechanism varies according to the type of equipment, most systems rely on specialized sensors that detect respiratory changes and convert them into electronic signals. These signals are processed by internal software and displayed as numerical measurements, flow-volume loops, volume-time curves, and other graphical representations of lung function.
The process begins when a patient breathes through a mouthpiece connected to the machine. Depending on the test being performed, the patient may be instructed to breathe normally, inhale as deeply as possible, exhale forcefully, or follow a specific breathing sequence. The machine detects the resulting changes and records the information for analysis.
The general operating process involves several stages:
1. Airflow detection: During spirometry, the patient breathes through a mouthpiece connected to a flow sensor. As air moves through the system, the sensor detects the direction and rate of airflow. Depending on the technology used, the machine may measure flow directly or calculate it from pressure changes across a calibrated resistance.
2. Volume calculation: The machine uses the measured airflow over time to calculate the volume of air inhaled or exhaled. This allows it to determine measurements such as tidal volume, vital capacity, and forced vital capacity. For example, when a patient takes a deep breath and then exhales forcefully, the machine records the volume expelled during the maneuver.
3. Pressure and lung volume assessment: More advanced systems use pressure measurements to estimate lung volumes that cannot be obtained through ordinary spirometry. In body plethysmography, the patient sits inside an enclosed chamber called a body box. Pressure changes inside the chamber and at the patient’s mouth are measured during specific breathing maneuvers. These measurements are used to calculate thoracic gas volume and other lung volume parameters.
4. Gas concentration measurement: During DLCO testing, the patient inhales a carefully controlled test gas containing a small amount of carbon monoxide. The machine measures the gas concentration in the inhaled and exhaled samples to estimate how effectively carbon monoxide moves from the alveoli into the blood. This provides information about the lungs’ diffusion capacity.
5. Data processing and result display: The machine’s software processes the signals collected by its sensors and converts them into respiratory measurements. Depending on the test, the results may include FEV1, FVC, FEV1/FVC, total lung capacity, residual volume, and DLCO. The software may also generate graphs that allow healthcare professionals to examine breathing patterns and identify abnormalities.
The specific technology used depends on the type of pulmonary function test being performed.
How spirometry works: During a spirometry test, the patient is usually instructed to sit upright, place their lips firmly around the mouthpiece, inhale fully, and then exhale as forcefully and completely as possible. The spirometer measures the volume of air expelled and the speed at which it leaves the lungs. It records the forced vital capacity and the amount of air exhaled during the first second, known as FEV1. The relationship between these values helps healthcare professionals assess whether airflow is obstructed.
How body plethysmography works: In body plethysmography, the patient sits inside an airtight chamber, commonly called a body box. They breathe through a mouthpiece while the equipment records pressure changes within the chamber and at the mouth. Using principles related to Boyle’s law, the system calculates the volume of gas present in the chest. This allows measurement of functional residual capacity and calculation of other absolute lung volumes, including residual volume and total lung capacity. This method is especially useful when assessing air trapping and hyperinflation in patients with obstructive lung diseases.
How DLCO testing works: During DLCO testing, the patient exhales to a specified level, inhales a test gas mixture containing a small concentration of carbon monoxide, briefly holds their breath, and then exhales. The machine analyzes the gas sample to determine how much carbon monoxide has been absorbed during the breath-holding period. Because carbon monoxide binds readily to hemoglobin, its uptake provides an estimate of the lungs’ ability to transfer gas across the alveolar-capillary membrane. The result is used to assess diffusion capacity and may help identify abnormalities associated with emphysema, pulmonary fibrosis, and other conditions affecting gas exchange.
These different operating principles explain why a basic spirometer cannot replace a complete pulmonary function testing system. Although spirometry provides valuable information about airflow and expiratory volumes, additional technologies are necessary to measure absolute lung volumes and diffusion capacity.
These different operating principles explain why a basic spirometer cannot replace a complete pulmonary function testing system. Although spirometry provides valuable information about airflow and expiratory volumes, additional technologies are necessary to measure absolute lung volumes and diffusion capacity.
Main Components and Measurements
A PFT machine consists of several interconnected components that work together to collect, process, display, and store respiratory measurements. The exact configuration depends on whether the equipment is a basic spirometer, a portable pulmonary function testing device, or a comprehensive system capable of performing multiple function tests. However, most systems contain a breathing interface, airflow or pressure sensors, measurement chambers or gas analyzers, electronic processing units, and software for displaying and interpreting test results.
Understanding these components is important because each performs a specific function in the testing process. The mouthpiece provides the connection between the patient’s respiratory system and the equipment, sensors detect changes in airflow or pressure, and the software converts the collected signals into clinically meaningful measurements.
Main components of a PFT machine
1. Mouthpiece and breathing interface: The mouthpiece is the part through which the patient breathes during pulmonary function testing. It is usually connected to a flow sensor through a short tube or breathing circuit. The patient places their lips firmly around it to create an airtight seal and prevent air leakage during testing. Some systems use disposable mouthpieces or specialized bacterial and viral filters to reduce the risk of cross-contamination. A nose clip may also be used during spirometry to prevent air from escaping through the nose and ensure that the measured airflow passes through the equipment.
2. Flow sensors and transducers: These components detect the movement of air during inhalation and exhalation. Depending on the machine’s design, the sensor may use pneumotachography, turbine technology, ultrasonic measurement, or other flow-measuring methods. A pneumotachograph, for example, measures the pressure difference across a known resistance as air passes through it. The resulting signal is used to calculate airflow and determine the volume of air moved over time. Accurate flow measurement is essential for obtaining reliable spirometry values, including FEV1 and FVC.
3. Pressure sensors: Pressure transducers detect changes in pressure within the breathing circuit or testing chamber. They are particularly important in body plethysmography, where pressure changes inside the body box and at the patient’s mouth are used to calculate thoracic gas volume. These measurements help determine absolute lung volumes and assess abnormalities such as air trapping and hyperinflation.
4. Gas analyzers: Advanced pulmonary function testing systems contain gas analyzers that measure the concentration of specific gases in inhaled and exhaled air. These components are particularly important during DLCO testing, where the machine analyzes the amount of carbon monoxide remaining in the exhaled sample after a controlled breath-holding period. By comparing the inhaled and exhaled gas concentrations, the system estimates the lungs’ diffusion capacity.
5. Body plethysmography chamber: In systems designed for body plethysmography, the body box is an enclosed chamber in which the patient sits during lung volume assessment. It is fitted with pressure sensors and connected to a breathing circuit. As the patient performs specific breathing maneuvers against a temporarily closed shutter, the machine records changes in pressure and calculates the volume of gas within the thorax. This component allows measurements that cannot be obtained through ordinary spirometry.
6. Electronic processing unit: The processing unit receives signals from the machine’s sensors and converts them into numerical measurements. It performs calculations involving airflow, volume, pressure, and gas concentration, depending on the test being conducted. For example, during spirometry, it integrates airflow over time to calculate the volume of air exhaled. It also helps generate flow-volume loops and volume-time curves for clinical assessment.
7. Display screen and testing software: The display provides a visual representation of the measurements collected during testing. It may show numerical values, graphs, reference ranges, and comparisons between measured and predicted lung function. The software also stores patient information, records test sessions, and generates reports that healthcare professionals can review. Some advanced systems provide automated quality indicators and comparison tools to help identify technically unacceptable or inconsistent measurements.
Key measurements obtained using a PFT machine
The measurements recorded by a PFT machine depend on the specific pulmonary function tests available. Some parameters assess the movement of air through the respiratory system, while others evaluate lung capacity, residual gas volume, and the efficiency of gas exchange.
The major measurements include:
| Measurement | Meaning and clinical significance |
|---|---|
| Forced Vital Capacity (FVC) | The total volume of air a person can forcibly exhale after taking a full inspiration. It helps assess expiratory capacity and identify possible ventilatory abnormalities. |
| Forced Expiratory Volume in One Second (FEV1) | The volume of air forcibly exhaled during the first second of an FVC maneuver. It is important for assessing expiratory airflow limitation. |
| FEV1/FVC Ratio | The proportion of the forced vital capacity exhaled during the first second. A reduced ratio may indicate an obstructive ventilatory pattern. |
| Tidal Volume (TV) | The amount of air inhaled or exhaled during normal, relaxed breathing. It reflects ordinary breathing activity rather than maximal respiratory effort. |
| Vital Capacity (VC) | The maximum volume of air that can be exhaled after taking the deepest possible breath. It provides information about the functional capacity of the lungs. |
| Total Lung Capacity (TLC) | The total amount of air contained in the lungs after maximal inspiration. It includes all lung volume compartments and helps identify restrictive ventilatory defects. |
| Residual Volume (RV) | The amount of air remaining in the lungs after maximal forced expiration. It cannot be measured using basic spirometry alone and requires additional testing methods. |
| Functional Residual Capacity (FRC) | The amount of air remaining in the lungs at the end of a normal, passive expiration. It provides information about the resting volume of the respiratory system. |
| Diffusing Capacity (DLCO) | A measurement of how effectively gas transfers from the alveoli into the pulmonary capillary blood. It is useful when evaluating conditions that affect the alveolar-capillary membrane or pulmonary gas exchange. |
| Peak Expiratory Flow (PEF) | The highest airflow achieved during a forceful expiration. It can help assess the degree of airflow limitation, particularly in patients with asthma. |
These measurements provide different types of information and should be interpreted according to the specific test performed.
For instance, FEV1 and FVC are primarily obtained through spirometry, whereas TLC, RV, and FRC require lung volume measurement techniques such as body plethysmography or gas dilution. DLCO is obtained through a specialized diffusion test rather than ordinary spirometry. This distinction is important because a machine that measures airflow alone cannot provide all the information needed for a complete pulmonary function assessment.
Understanding how the measurements relate to respiratory conditions
The clinical importance of these measurements becomes clearer when they are considered in relation to different lung conditions.
– Obstructive lung diseases: Conditions such as asthma and COPD interfere with the movement of air through the airways, particularly during expiration. Spirometry may demonstrate a reduced FEV1/FVC ratio, indicating airflow obstruction. In some patients, lung volume testing may also reveal increased residual volume due to air trapping.
– Restrictive lung diseases: Conditions such as pulmonary fibrosis can reduce the ability of the lungs to expand fully. These patients may demonstrate reduced FVC on spirometry, although lung volume testing is needed to establish whether total lung capacity is reduced and confirm a restrictive ventilatory defect.
– Conditions affecting gas exchange: Diseases such as emphysema and pulmonary fibrosis may interfere with the transfer of gases across the alveolar-capillary membrane. DLCO testing helps evaluate this process by measuring diffusion capacity.
For example, two patients may both experience shortness of breath but have different pulmonary function test findings. One patient with COPD may demonstrate reduced FEV1/FVC and increased residual volume, suggesting airflow obstruction and air trapping. Another patient with pulmonary fibrosis may have reduced total lung capacity and diffusion capacity, suggesting restricted lung expansion and impaired gas transfer. These differences demonstrate why combining several measurements can provide a more complete assessment than relying on a single spirometry value.
It is also important to recognize that PFT measurements are compared with appropriate reference values rather than interpreted using one universal normal number. Predicted values and lower limits of normal are influenced by factors such as age, height, and the reference equations used. The quality of the breathing maneuver, equipment accuracy, and patient effort must also be considered when reviewing results.
A properly functioning PFT machine therefore does more than record how much air a person breathes. It provides a structured assessment of airflow, lung volume, and gas transfer, allowing healthcare professionals to identify patterns of respiratory impairment and determine when additional investigations may be necessary. Understanding the individual components and measurements is essential for appreciating how different pulmonary function tests contribute to the evaluation of respiratory health.
Types of PFT Machines
PFT machines are available in different configurations, ranging from simple devices that measure airflow to sophisticated systems capable of evaluating several aspects of respiratory function. The type of equipment used depends on the clinical purpose of the assessment, the measurements required, the patient’s condition, and the testing capabilities of the healthcare facility. Some devices are designed primarily for spirometry, while others combine multiple testing technologies to provide a more comprehensive evaluation of lung function, including lung volume measurements and diffusion capacity.
Understanding the different types of PFT machines is important because not all devices perform the same function or provide the same level of diagnostic information. For example, a portable spirometer can measure forced vital capacity (FVC) and forced expiratory volume in one second (FEV1), but it cannot independently measure residual volume or total lung capacity. A full pulmonary function testing system, on the other hand, may incorporate spirometry, lung volume assessment, and DLCO testing within one integrated unit. Body plethysmography machines provide another specialized approach by measuring the amount of gas present in the thorax, including air that remains in the lungs after maximal expiration.
The main categories of equipment used in pulmonary function testing include spirometers and portable PFT machines, full pulmonary function testing systems, and body plethysmography machines. Although these devices share the general purpose of assessing respiratory function, they differ in their operating principles, measurement capabilities, and clinical applications.
Spirometers and Portable PFT Machines
A spirometer is a medical device used to measure the volume of air a person inhales and exhales, as well as the rate at which air moves through the respiratory system. It is one of the most commonly used types of PFT equipment because it provides important information about airflow and expiratory capacity. Spirometers are particularly useful in the initial assessment of patients with suspected obstructive lung diseases, including asthma and chronic obstructive pulmonary disease (COPD).
A spirometer works by detecting airflow through a mouthpiece connected to a measurement sensor. When a patient performs a breathing maneuver, the device records the movement of air and converts it into numerical values and graphical representations. Depending on the type of spirometer, measurements may be displayed as volume-time curves, flow-volume loops, and numerical readings.
The main measurements obtained through spirometry include:
- Forced Vital Capacity (FVC): The total amount of air a person can forcibly exhale after taking the deepest possible breath.
- Forced Expiratory Volume in One Second (FEV1): The volume of air exhaled during the first second of a forced expiratory maneuver.
- FEV1/FVC ratio: The proportion of the total forced vital capacity exhaled during the first second. A reduced ratio may indicate airflow obstruction.
- Peak Expiratory Flow (PEF): The highest airflow achieved during a forceful expiration.
- Forced Expiratory Flow (FEF): Measurements of airflow over specified portions of the forced expiratory maneuver.
These measurements help healthcare professionals evaluate how effectively air moves through the airways. For example, a patient with asthma may demonstrate reduced expiratory airflow during an episode of airway narrowing. Following administration of a bronchodilator, spirometry can be repeated to assess whether lung function improves. This is known as bronchodilator responsiveness testing and provides information about changes in airflow following medication.
Types of spirometers
Spirometers are available in several designs, with differences in their measurement technology, portability, and intended clinical use.
1. Desktop diagnostic spirometers: These are commonly used in hospitals, respiratory clinics, medical centers, and pulmonary function laboratories. They are generally connected to a computer or contain an integrated display and software system for recording, analyzing, and storing patient measurements. Desktop spirometers may include advanced reporting features, predicted reference values, and graphical displays that help healthcare professionals evaluate respiratory function. Some models also support bronchodilator testing and automated quality checks.
2. Handheld spirometers: Handheld devices are compact instruments designed for convenient respiratory assessment. They usually contain an integrated flow sensor and display screen, allowing measurements to be obtained without a large testing workstation. Depending on the model, they may measure FEV1, FVC, FEV1/FVC, and peak expiratory flow. Their small size makes them useful in outpatient clinics, primary healthcare settings, occupational health assessments, and certain home-monitoring applications.
3. Portable spirometry systems: Portable spirometers are lightweight devices that may connect to a laptop, tablet, or dedicated mobile application. They offer more flexibility than traditional desktop systems because they can be transported between clinical departments, community healthcare facilities, and different testing locations. Some systems use wireless connectivity to transfer results into electronic medical records or other patient management platforms.
4. Office-based spirometry devices: These devices are designed for routine respiratory assessment in general medical practices and outpatient settings. They provide basic diagnostic spirometry without requiring a fully equipped pulmonary function laboratory. Healthcare providers may use them when evaluating patients with persistent cough, wheezing, shortness of breath, or suspected obstructive airway disease.
Portable PFT machines
Portable PFT machines are designed to provide respiratory measurements in locations where a conventional pulmonary function laboratory may not be available or practical. They vary considerably in capability. Some are essentially portable spirometers, while more advanced portable systems may offer additional measurements or connect to external testing modules.
Their portability makes them useful in several clinical situations:
- Primary healthcare facilities: Healthcare professionals can perform spirometry when assessing patients with suspected asthma, COPD, or other respiratory conditions.
- Community-based respiratory screening: Portable devices can support lung function assessments during outreach programs, occupational health evaluations, and community healthcare initiatives.
- Bedside assessments: Certain portable systems can be used to evaluate patients who may have difficulty traveling to a dedicated pulmonary function laboratory, provided they are clinically stable and able to perform the required maneuvers.
- Home monitoring: Selected devices allow patients with established respiratory conditions to record specific lung function measurements under an agreed monitoring plan. These readings can help identify changes that may require clinical review.
Advantages and limitations of spirometers and portable PFT machines
Spirometers offer several advantages in respiratory assessment. They are generally easier to operate than comprehensive pulmonary function testing systems, require less space, and can provide useful measurements within a relatively short testing session. Portable models also improve access to spirometry in healthcare facilities that lack dedicated respiratory laboratories.
However, their measurement capabilities are limited. Basic spirometry measures the air that moves into and out of the lungs during specific breathing maneuvers, but it cannot directly measure all lung volume compartments. In particular, residual volume (RV), functional residual capacity (FRC), and total lung capacity (TLC) cannot be determined through ordinary spirometry alone. Additional methods, such as body plethysmography or gas dilution techniques, are needed to obtain these measurements.
Another important consideration is test quality. Although a portable device may be convenient, its results are only useful when the equipment is appropriately calibrated or verified, the patient follows the testing instructions, and acceptable breathing maneuvers are obtained. Device portability does not automatically mean that every model has the same diagnostic capabilities or accuracy as equipment used in a specialized pulmonary function laboratory.
For example, a primary healthcare clinic may use a portable spirometer to assess a patient presenting with persistent wheezing and suspected COPD. If the spirometry results indicate airflow obstruction, the healthcare provider may use the findings alongside the patient’s symptoms and medical history to guide further evaluation. If additional information about lung volumes or diffusion capacity is required, the patient may need referral for more comprehensive pulmonary function testing.
Full Pulmonary Function Testing Systems
Full pulmonary function testing systems are advanced diagnostic platforms designed to evaluate several aspects of respiratory function within one integrated setup. Unlike basic spirometers, which primarily measure airflow and the volume of air inhaled or exhaled, these systems can perform multiple types of pulmonary function tests, including spirometry, lung volume measurements, and diffusion capacity assessments. They are commonly found in hospital respiratory departments, specialized pulmonary function laboratories, and medical centers where detailed evaluation of lung function is required.
A full pulmonary function testing machine typically combines different measurement technologies, sensors, gas analyzers, and computerized software to provide a broader assessment of the respiratory system. Depending on its configuration, it may include modules for spirometry, body plethysmography, gas dilution, and DLCO testing. This allows healthcare professionals to evaluate not only how much air a patient can move but also how much air remains in the lungs after expiration and how effectively gases pass from the alveoli into the bloodstream.
One of the main advantages of a full pulmonary function testing system is its ability to assess abnormalities that cannot be adequately characterized through spirometry alone. For example, a patient may demonstrate a reduced FVC during spirometry, but this finding does not necessarily confirm restrictive lung disease. The reduction could also result from air trapping associated with an obstructive condition. Measuring total lung capacity through additional lung volume testing helps distinguish between these possibilities. Similarly, DLCO testing provides information about gas transfer that cannot be obtained from ordinary spirometry.
Major functions of full pulmonary function testing systems
A comprehensive PFT system may perform several assessments, each examining a different aspect of respiratory physiology.
1. Diagnostic spirometry: The system measures forced vital capacity, forced expiratory volume in one second, and the FEV1/FVC ratio. These measurements help identify airflow obstruction and evaluate expiratory function. The machine also generates flow-volume loops and volume-time curves, which allow healthcare professionals to assess the quality and characteristics of the patient’s breathing maneuvers.
2. Lung volume measurement: Advanced systems measure lung volumes such as total lung capacity, residual volume, and functional residual capacity. Depending on the available technology, these measurements may be obtained through body plethysmography or gas dilution techniques. They are particularly useful when investigating suspected restrictive lung disease, air trapping, or pulmonary hyperinflation.
3. Diffusion capacity assessment: Many full pulmonary function testing systems include a DLCO module that evaluates how efficiently gases move across the alveolar-capillary membrane. The test commonly involves inhaling a controlled gas mixture containing a small amount of carbon monoxide. The machine analyzes the exhaled sample to estimate the amount of carbon monoxide transferred into the pulmonary circulation.
4. Bronchodilator responsiveness testing: Some systems allow spirometry to be performed before and after administration of a bronchodilator. Comparing the measurements helps healthcare providers evaluate changes in expiratory airflow following medication. This is particularly relevant when investigating asthma and other conditions associated with variable airflow limitation.
5. Computerized analysis and reporting: Full testing systems use dedicated software to process measurements, display graphs, compare results with predicted reference values, and generate reports. The software may also store previous assessments, allowing healthcare professionals to examine changes in lung function over time.
Clinical applications of full pulmonary function testing systems
These systems are particularly useful when a patient requires a detailed respiratory assessment or when basic spirometry does not provide enough information to explain their symptoms.
For example, consider a patient presenting with persistent shortness of breath and a reduced FVC on spirometry. A basic spirometer may identify the abnormality but cannot determine whether the patient has a true restrictive ventilatory defect or reduced expiratory volume caused by air trapping. A full pulmonary function testing system can measure total lung capacity and residual volume to provide additional information. If total lung capacity is reduced, this supports a restrictive ventilatory defect. If residual volume is elevated, air trapping may be contributing to the abnormal spirometry findings.
Another example involves a patient with suspected emphysema. Spirometry may demonstrate airflow obstruction, while lung volume testing may reveal increased residual volume and total lung capacity due to air trapping and hyperinflation. DLCO testing may also demonstrate reduced diffusion capacity because destruction of alveolar walls reduces the surface area available for gas exchange. Combining these measurements provides a more detailed physiological assessment than using spirometry alone.
Advantages and limitations of full pulmonary function testing systems
Full pulmonary function testing systems offer several advantages:
- Comprehensive assessment: They provide measurements of airflow, lung volumes, and diffusion capacity, allowing several aspects of respiratory function to be evaluated.
- Improved diagnostic evaluation: Combining different tests helps distinguish obstructive, restrictive, and mixed ventilatory patterns.
- Disease monitoring: Repeated assessments allow healthcare providers to compare measurements and monitor changes in respiratory function.
- Integrated reporting: Computerized software simplifies data storage, graphical presentation, and comparison with reference values.
- Multiple testing capabilities: One integrated platform can support several respiratory investigations without requiring separate standalone devices for every test.
However, these systems also have limitations. They are generally more expensive than basic spirometers, require more laboratory space, and involve greater technical complexity. Some procedures require specialized training, careful patient instruction, and strict adherence to quality-control standards. In addition, not every full pulmonary function testing system contains every available testing module, so the specific capabilities of the equipment must be considered before selecting it.
For this reason, full pulmonary function testing systems are generally most appropriate for facilities that routinely perform detailed respiratory assessments, particularly when evaluating complex lung conditions or monitoring patients who require several different pulmonary function measurements.
Body Plethysmography Machines and the Body Box
Body plethysmography machines are specialized types of pulmonary function testing equipment used to measure absolute lung volumes and assess certain aspects of airway resistance. The procedure is performed using an enclosed chamber called a body box, which allows the machine to detect pressure changes associated with breathing. Unlike ordinary spirometry, which measures air moving through the mouthpiece, body plethysmography can estimate the amount of gas present within the thorax, including air that remains trapped in parts of the lungs.
This makes body plethysmography particularly useful when assessing patients with obstructive and restrictive lung conditions. For example, patients with severe COPD may have significant air trapping, meaning that some air remains in the lungs even after maximal expiration. A spirometer cannot directly measure this residual air, but a body plethysmography system can estimate it and calculate other absolute lung volumes. Similarly, patients with pulmonary fibrosis may require lung volume assessment to determine whether total lung capacity has been reduced because of restricted lung expansion.
Structure and components of a body plethysmography machine
A body plethysmography machine consists of several components that work together to measure pressure changes and calculate lung volumes.
1. The body box: This is the enclosed, airtight chamber in which the patient sits during testing. It is usually constructed from transparent materials so that the operator can observe the patient throughout the procedure. The chamber is designed to detect small pressure changes that occur as the patient breathes or performs specific respiratory maneuvers.
2. Mouthpiece and breathing circuit: The patient breathes through a mouthpiece connected to the measurement system. A nose clip is generally used to prevent air from escaping through the nose, ensuring that respiratory airflow passes through the mouthpiece. The breathing circuit may also contain a shutter or valve that temporarily closes the airflow pathway during specific measurements.
3. Pressure transducers: These sensors detect pressure changes inside the body box and within the breathing circuit. Their measurements are essential for calculating thoracic gas volume using established physical principles.
4. Flow sensors: These detect airflow during breathing maneuvers and may be used for linked spirometry measurements. They help the machine relate changes in airflow to the patient’s respiratory effort.
5. Shutter mechanism: The shutter is a temporary valve that closes the breathing circuit for a brief period during the procedure. When it closes, the patient performs gentle panting movements against the closed mouthpiece. These movements generate measurable pressure changes that are used to calculate thoracic gas volume.
6. Computerized analysis system: The computer receives pressure and flow signals, performs the required calculations, and displays lung volume measurements and related graphs. It may also store patient data and generate reports for clinical interpretation.
How body plethysmography works
Body plethysmography is based on Boyle’s law, which describes the relationship between the pressure and volume of a gas when temperature remains constant. In simple terms, when a gas is compressed, its pressure increases, and when it expands, its pressure decreases.
During the test, the patient sits inside the body box and breathes normally through a mouthpiece. Once a stable breathing pattern is established, the machine briefly closes the shutter. The patient is then instructed to make gentle panting movements against the closed mouthpiece.
Although no air moves through the closed breathing circuit during this brief maneuver, the patient’s chest continues to move. As the chest expands and contracts, the gas inside the lungs changes in volume and pressure. These changes produce corresponding pressure variations within the body box. The machine records these pressure differences and uses them to calculate the amount of gas inside the thorax.
The general testing sequence involves:
- The patient enters the body box and sits comfortably.
- A nose clip and mouthpiece are positioned correctly to establish an airtight breathing connection.
- The patient breathes normally until a stable end-expiratory lung volume is reached.
- The shutter temporarily closes the breathing circuit.
- The patient performs several gentle panting movements against the closed shutter.
- The machine records pressure changes inside the chamber and at the mouthpiece.
- The software calculates thoracic gas volume and uses additional measurements to determine other lung volumes.
The procedure requires proper patient instruction because excessive panting, air leakage, unstable breathing, or poor mouthpiece positioning can affect measurement quality. Patients must also remain relaxed and follow the operator’s instructions throughout the test.
Lung measurements obtained through body plethysmography
One of the major advantages of body plethysmography is its ability to measure lung volumes that cannot be obtained through basic spirometry.
Important measurements include:
- Functional Residual Capacity (FRC): The volume of air remaining in the lungs after a normal, passive expiration. Body plethysmography measures thoracic gas volume at the measurement point, which is used to determine plethysmographic FRC.
- Residual Volume (RV): The amount of air remaining in the lungs after the patient exhales as completely as possible. It is calculated using FRC and expiratory reserve volume.
- Total Lung Capacity (TLC): The total amount of air contained in the lungs following maximal inspiration. It includes all lung volume compartments and is calculated using FRC and inspiratory capacity or residual volume and vital capacity.
- Airway Resistance: A measurement of the resistance encountered by air as it moves through the respiratory airways. It provides information about how easily air flows through the respiratory system.
- Thoracic Gas Volume (TGV): The volume of compressible gas within the thorax at the time of airway occlusion during the plethysmographic maneuver.
These measurements provide useful information when investigating conditions involving reduced lung expansion, air trapping, or pulmonary hyperinflation.
Clinical importance of body plethysmography
Body plethysmography is particularly valuable when evaluating patients whose respiratory symptoms or initial spirometry findings require further investigation.
For example:
- COPD and emphysema: Patients with obstructive lung diseases may experience air trapping because narrowed airways make it difficult to expel air completely. Body plethysmography can demonstrate increased residual volume and functional residual capacity. In more advanced cases, total lung capacity may also be increased, indicating pulmonary hyperinflation.
- Pulmonary fibrosis: Scarring of the lung tissue reduces its ability to expand. Body plethysmography can identify reduced total lung capacity, supporting the presence of a restrictive ventilatory defect.
- Unexplained shortness of breath: When a patient has persistent breathing problems but spirometry does not fully explain their symptoms, lung volume measurements may provide additional information about respiratory mechanics.
- Suspected air trapping: A patient may have a reduced FVC on spirometry without having true restriction. Measuring total lung capacity and residual volume helps determine whether air trapping contributes to the reduced expiratory volume.
An important advantage of body plethysmography is that it can measure gas present in poorly ventilated or noncommunicating regions of the lungs. Gas dilution techniques may underestimate lung volume when certain regions do not communicate adequately with the mouthpiece. This distinction can be particularly relevant in patients with severe obstructive lung disease.
However, body plethysmography requires specialized equipment, trained operators, appropriate calibration, and patient cooperation. Some individuals may experience discomfort or anxiety when sitting inside the enclosed chamber, particularly those with claustrophobia. The procedure must therefore be explained carefully, and the patient should be informed that communication with the operator is maintained throughout the assessment.
Overall, body plethysmography provides information that complements spirometry and other pulmonary function tests. By measuring thoracic gas volume, residual volume, total lung capacity, and airway resistance, it helps healthcare professionals investigate respiratory abnormalities that may not be fully explained by airflow measurements alone.
Advantages and limitations of body plethysmography
Body plethysmography offers several advantages over basic spirometry and other lung volume measurement techniques:
- It measures absolute lung volumes, including residual volume and total lung capacity.
- It can detect air trapping and pulmonary hyperinflation, particularly in patients with obstructive lung diseases.
- It measures thoracic gas volume, including gas in poorly ventilated or noncommunicating lung regions.
- It provides additional information about airway resistance and respiratory mechanics.
- It complements spirometry when investigating suspected restrictive or obstructive ventilatory abnormalities.
Despite these advantages, body plethysmography has certain limitations. The equipment is relatively expensive, requires dedicated laboratory space, and needs trained personnel to operate and interpret the measurements. Patients must also be able to sit inside the enclosed chamber and perform the required breathing maneuvers. Claustrophobia, difficulty maintaining a proper mouthpiece seal, and inconsistent breathing efforts may affect the quality of the results.
It is also important to recognize that body plethysmography does not replace other pulmonary function tests. For a comprehensive respiratory assessment, its measurements are often interpreted alongside spirometry and DLCO testing. Each procedure provides different physiological information, and combining their findings allows healthcare professionals to develop a more complete understanding of a patient’s lung function.
Distinguishing the three main types of PFT machines
| Feature | Spirometers and portable PFT machines | Full PFT systems | Body plethysmography machines |
|---|---|---|---|
| Primary function | Measures airflow and breathing volumes | Performs multiple pulmonary function tests | Measures absolute lung volumes and airway resistance |
| Main measurements | FEV1, FVC, FEV1/FVC, PEF | Spirometry, lung volumes, DLCO | TGV, FRC, RV, TLC, airway resistance |
| Equipment design | Desktop or handheld devices | Integrated diagnostic workstation | Enclosed body box with pressure sensors |
| Common applications | Initial respiratory assessment and routine spirometry | Comprehensive respiratory evaluation | Assessment of air trapping, hyperinflation, and restrictive defects |
| Typical setting | Clinics, hospitals, and primary healthcare facilities | Specialized pulmonary function laboratories | Respiratory and pulmonary function laboratories |
The choice of equipment depends on the clinical information required. A portable spirometer may be sufficient when the primary objective is to assess airflow obstruction, whereas a full pulmonary function testing system is more appropriate when several aspects of respiratory function need to be investigated. Body plethysmography is particularly valuable when accurate measurement of absolute lung volumes and assessment of air trapping are required.
Understanding these differences helps healthcare professionals recognize the capabilities and limitations of each PFT machine and appreciate why different devices are used for different respiratory assessments.
Types of Pulmonary Function Tests
Pulmonary function tests (PFTs) are a group of diagnostic procedures used to evaluate how well the lungs and respiratory system perform their primary functions. These tests assess different aspects of breathing, including airflow, lung volume, respiratory mechanics, and the movement of gases between the alveoli and bloodstream. Although the procedures differ in their measurement techniques, they work together to provide information about the structural and functional performance of the respiratory system.
The type of pulmonary function test performed depends on the patient’s symptoms, medical history, suspected lung condition, and the clinical information required. For example, spirometry is commonly used to assess airflow limitation in patients with suspected asthma or COPD, while lung volume testing helps determine whether the lungs can expand adequately or retain excessive amounts of air. DLCO testing evaluates gas transfer across the alveolar-capillary membrane and may be requested when conditions affecting the lung tissue or pulmonary circulation are suspected.
A PFT machine may perform one or several of these assessments, depending on its configuration. Basic spirometers primarily measure airflow and expiratory volumes, whereas advanced pulmonary function testing systems may combine spirometry, lung volume measurement, and diffusion capacity testing. Understanding the differences between these procedures is important because each test provides distinct information, and no single measurement can describe every aspect of respiratory function.
Spirometry
Spirometry is one of the most frequently performed pulmonary function tests and is used to measure how much air a person can inhale and exhale, as well as how quickly air moves out of the lungs. It provides important information about airflow and expiratory function, making it particularly useful when evaluating patients with suspected obstructive airway diseases such as asthma and chronic obstructive pulmonary disease (COPD). The procedure is performed using a spirometer, which records airflow and calculates the volume of air moved during specific breathing maneuvers.
During a spirometry test, the patient breathes through a mouthpiece connected to the PFT machine. They are generally instructed to inhale as deeply as possible and then exhale forcefully and completely into the device. The machine detects the airflow generated during expiration and records the volume of air expelled over time. Depending on the testing protocol, additional breathing maneuvers may be performed to measure different aspects of respiratory function.
The main purpose of spirometry is to determine whether airflow is normal or restricted during expiration. In healthy individuals, air moves relatively freely through the airways, allowing a substantial proportion of the forced vital capacity to be expelled during the first second of expiration. However, conditions that narrow or obstruct the airways can slow expiratory airflow, reducing the amount of air expelled during that initial second.
Key measurements obtained during spirometry
Several important measurements are recorded during a spirometry test. Each provides different information about the patient’s ability to move air through the respiratory system.
1. Forced Vital Capacity (FVC): FVC refers to the total volume of air a person can forcibly exhale after taking the deepest possible breath. The patient first inhales fully and then exhales as forcefully and completely as possible. The PFT machine measures the total amount of air expelled during this maneuver. A reduced FVC may occur in restrictive lung diseases, severe airflow obstruction with air trapping, or when the patient cannot perform the maneuver adequately. Therefore, a low FVC alone does not confirm restrictive lung disease; total lung capacity must be assessed to establish whether restriction is present.
2. Forced Expiratory Volume in One Second (FEV1): FEV1 measures the volume of air forcibly exhaled during the first second of an FVC maneuver. It is an important indicator of expiratory airflow because airway narrowing makes it more difficult for air to leave the lungs rapidly. Patients with COPD, asthma, and other obstructive conditions may demonstrate reduced FEV1. The measurement is also useful for assessing changes in airflow following treatment.
3. FEV1/FVC ratio: This represents the proportion of the total forced vital capacity that is exhaled during the first second. It is calculated by comparing FEV1 with FVC. A reduced ratio is an important indicator of airflow obstruction. For example, a patient may have an FEV1 of 1.5 liters and an FVC of 3 liters, producing an FEV1/FVC ratio of 0.50, or 50%. This suggests that the patient can expel only half of their total forced expiratory volume during the first second. The result must be compared with the appropriate lower limit of normal rather than relying on a single fixed cutoff for every patient.
4. Peak Expiratory Flow (PEF): PEF measures the highest rate of airflow achieved during a forceful expiration following maximal inspiration. It is commonly expressed in liters per minute. A reduced peak expiratory flow may indicate narrowed airways or reduced expiratory effort. It is particularly useful in monitoring patients with asthma, where changes in peak flow may reflect variations in airway narrowing.
5. Forced Expiratory Flow (FEF): FEF refers to airflow measurements recorded during specific portions of the forced expiration. One commonly reported measurement is FEF25–75%, which represents the average flow during the middle portion of the FVC maneuver. Although it may provide supplementary information, it has considerable variability and should not be used alone to diagnose small-airway disease.
How the spirometry test is performed
The accuracy of spirometry depends heavily on patient cooperation and the ability to perform acceptable breathing maneuvers. Before testing, the healthcare professional explains the procedure and demonstrates the required breathing technique. The patient is usually seated upright, and a nose clip may be applied to prevent air from escaping through the nasal passages.
The general procedure involves the following steps:
- The patient sits comfortably and receives instructions about the test.
- A disposable or appropriately prepared mouthpiece is connected to the spirometer.
- The patient places their lips firmly around the mouthpiece to prevent air leakage.
- They are instructed to take a deep breath until their lungs are fully inflated.
- The patient exhales as forcefully and rapidly as possible and continues until the lungs are sufficiently emptied.
- The PFT machine records the volume and rate of airflow throughout expiration.
- The maneuver is repeated to obtain acceptable and repeatable measurements.
Several attempts may be required because the results depend on the patient’s effort and technique. Coughing during the first second, hesitation at the beginning of expiration, early termination, or leakage around the mouthpiece can affect the measurements. Healthcare professionals therefore assess the quality of each maneuver before accepting the results.
Pre-bronchodilator and post-bronchodilator spirometry
Spirometry may also be performed before and after administering a bronchodilator medication. This procedure is known as bronchodilator responsiveness testing and helps assess whether airflow improves following the use of medication that relaxes the airway muscles.
The process generally involves:
- Pre-bronchodilator spirometry: Initial measurements of FEV1 and FVC are recorded before medication is administered. These values provide a baseline assessment of the patient’s airflow and expiratory capacity.
- Bronchodilator administration: The patient receives a prescribed inhaled bronchodilator, which acts by relaxing the smooth muscles surrounding the airways.
- Post-bronchodilator spirometry: After the appropriate waiting period, the spirometry test is repeated, and the new measurements are compared with the baseline values.
For example, a patient with suspected asthma may initially demonstrate reduced FEV1 because of airway narrowing. Following bronchodilator administration, FEV1 may increase, indicating improved expiratory airflow. The change helps characterize bronchodilator responsiveness, although it does not independently establish or exclude asthma. Similarly, patients with COPD may demonstrate some improvement after bronchodilator administration, even though persistent airflow obstruction remains.
Clinical importance of spirometry
Spirometry is valuable in the assessment and monitoring of several respiratory conditions. Its applications include:
- Asthma: Helps identify variable expiratory airflow limitation and assess changes in lung function following bronchodilator treatment.
- COPD: Provides evidence of persistent airflow obstruction and helps characterize the degree of spirometric impairment.
- Pulmonary fibrosis: May reveal reduced FVC, although additional lung volume measurements are required to confirm a restrictive ventilatory defect.
- Preoperative respiratory assessment: May be requested in selected patients when information about respiratory function is relevant to surgical planning.
- Occupational respiratory assessment: Helps monitor lung function in individuals exposed to dust, fumes, chemicals, or other substances that may affect respiratory health.
- Treatment monitoring: Repeated measurements allow healthcare providers to compare lung function over time and evaluate changes associated with disease progression or treatment.
An important distinction is that spirometry measures the movement of air rather than the total amount of air remaining in the lungs. Consequently, it cannot directly determine residual volume, functional residual capacity, or total lung capacity. When these measurements are needed, additional pulmonary function tests must be performed.
Lung Volume Testing
Lung volume testing is a pulmonary function assessment used to determine the total amount of air the lungs can contain and how much remains inside them after different stages of breathing. Unlike spirometry, which measures the air that moves into and out of the lungs, lung volume testing evaluates additional air compartments that cannot be measured through ordinary spirometric maneuvers. These measurements are important when investigating conditions that reduce lung expansion, cause excessive air retention, or interfere with normal respiratory mechanics.
The primary purpose of lung volume testing is to assess the capacity of the lungs and identify abnormalities in the distribution of air within the respiratory system. For example, patients with pulmonary fibrosis may have reduced lung volumes because stiffened lung tissue restricts expansion. In contrast, individuals with COPD or emphysema may retain excessive air after expiration because narrowed or damaged airways make it difficult to empty the lungs completely. Measuring lung volumes helps healthcare professionals distinguish between these different patterns of respiratory impairment.
A PFT machine capable of performing lung volume testing uses specialized measurement techniques, including body plethysmography, gas dilution, and gas washout methods. These techniques determine the volume of gas within the lungs by assessing pressure changes or tracking the movement of specific gases during breathing.
Major lung volumes and capacities measured
Lung volume testing involves several measurements that describe different compartments of air within the respiratory system. Understanding these values is important because they provide information about lung expansion, air retention, and respiratory efficiency.
1. Tidal Volume (TV): This is the amount of air inhaled or exhaled during normal, relaxed breathing. In a healthy resting adult, tidal volume is approximately 500 mL, although it varies according to body size, physical activity, age, and other physiological factors. It reflects the amount of air exchanged during ordinary respiratory cycles.
2. Inspiratory Reserve Volume (IRV): This refers to the additional amount of air a person can inhale after completing a normal inspiration. For example, after taking an ordinary breath, an individual may be instructed to inhale as deeply as possible. The additional air drawn into the lungs represents the inspiratory reserve volume.
3. Expiratory Reserve Volume (ERV): This is the additional amount of air that can be forcibly exhaled after completing a normal expiration. It represents the volume of air that can be expelled beyond what is normally breathed out during quiet breathing.
4. Residual Volume (RV): Residual volume is the amount of air remaining in the lungs after a person has exhaled as completely as possible. It is important because the lungs never become completely empty, even after maximal expiration. Increased RV may indicate air trapping, which is commonly associated with COPD and emphysema.
5. Functional Residual Capacity (FRC): FRC is the amount of air remaining in the lungs at the end of a normal, passive expiration. It consists of residual volume and expiratory reserve volume. This measurement provides information about the resting volume of the respiratory system and may be altered in conditions involving air trapping or reduced lung compliance.
6. Vital Capacity (VC): Vital capacity is the maximum amount of air a person can exhale after taking the deepest possible breath. It represents the combined volume of inspiratory reserve volume, tidal volume, and expiratory reserve volume.
7. Total Lung Capacity (TLC): TLC represents the total amount of air contained in the lungs following maximal inspiration. It includes all four primary lung volume compartments and is particularly important when evaluating suspected restrictive lung disease.
Methods used for lung volume measurement
There are several techniques used to measure lung volumes, with the choice depending on the equipment available, the patient’s condition, and the clinical information required.
1. Body plethysmography
Body plethysmography is a widely used method for measuring absolute lung volumes. The procedure is performed using a specialized PFT machine equipped with an enclosed chamber called a body box. The patient sits inside the chamber and breathes through a mouthpiece connected to the testing system.
During the procedure, the patient performs gentle breathing maneuvers while the machine measures pressure changes inside the chamber and at the mouthpiece. These measurements are used to calculate thoracic gas volume based on Boyle’s law, which describes the relationship between gas pressure and volume.
Body plethysmography is particularly useful because it measures compressible gas within the thorax, including gas trapped in poorly ventilated lung regions. This makes it valuable when assessing patients with severe obstructive lung diseases, where some areas of the lungs may not communicate effectively with the mouthpiece.
For example, a patient with emphysema may have extensive air trapping caused by the destruction of alveolar structures and reduced elastic recoil. Body plethysmography can demonstrate increased residual volume and total lung capacity, providing evidence of air trapping and pulmonary hyperinflation.
2. Gas dilution techniques
Gas dilution methods measure lung volumes by introducing a known concentration of an inert tracer gas into the patient’s breathing circuit and observing how it distributes throughout the ventilated portions of the lungs.
Two commonly used approaches include helium dilution and nitrogen washout.
- Helium dilution: The patient breathes through a closed circuit containing a known concentration of helium. As the helium mixes with the air already present in the lungs, its concentration decreases. The PFT machine measures this change and calculates the volume of gas with which the helium has equilibrated.
- Nitrogen washout: The patient breathes a gas mixture containing a high concentration of oxygen, commonly 100% oxygen, which gradually replaces nitrogen within the lungs. The machine measures the nitrogen eliminated during breathing and uses this information to estimate lung volume.
Unlike body plethysmography, gas dilution and washout methods measure gas that communicates with the breathing circuit. Consequently, they may underestimate lung volume in patients with significant air trapping or poorly ventilated lung regions.
Clinical significance of lung volume testing
Lung volume measurements are particularly useful when spirometry produces abnormal findings that require further investigation. For example, a reduced FVC may suggest a restrictive ventilatory pattern, but it does not independently confirm restrictive lung disease. Measuring total lung capacity helps determine whether the lungs genuinely have a reduced maximum volume.
The results are particularly useful in the following conditions:
- Pulmonary fibrosis: Scarring and thickening of lung tissue reduce its ability to expand, often resulting in decreased total lung capacity and vital capacity.
- COPD: Airway narrowing and reduced elastic recoil may prevent complete expiration, causing increased residual volume and functional residual capacity.
- Emphysema: Destruction of alveolar walls and loss of elastic recoil can lead to air trapping and pulmonary hyperinflation, reflected by increased RV and TLC.
- Severe asthma: During significant airflow obstruction, patients may experience air trapping and increased lung volumes. These abnormalities may improve as airway narrowing responds to treatment.
For example, consider two patients who both demonstrate reduced FVC during spirometry. The first patient has pulmonary fibrosis, while the second has severe COPD with air trapping. Further testing may reveal reduced TLC in the first patient, confirming a restrictive ventilatory defect. The second patient may demonstrate increased RV and a relatively preserved or elevated TLC, indicating that trapped air contributes to the reduced FVC. This illustrates why lung volume measurements are important when distinguishing between different causes of abnormal spirometry results.
DLCO Testing and Lung Diffusion
DLCO testing, also known as the diffusing capacity of the lung for carbon monoxide test, is a pulmonary function assessment used to evaluate how effectively gases move from the air spaces of the lungs into the pulmonary bloodstream. It provides information about the efficiency of gas exchange across the alveolar-capillary membrane, which is the thin barrier separating air within the alveoli from blood circulating through the pulmonary capillaries.
Under normal conditions, oxygen moves from the alveoli into the bloodstream, where it binds to hemoglobin and is transported to body tissues. Carbon dioxide moves in the opposite direction, passing from the blood into the alveoli before being exhaled. This exchange depends on several factors, including the surface area available for gas transfer, the thickness of the alveolar-capillary membrane, pulmonary capillary blood volume, and the availability of hemoglobin.
When disease affects the alveoli, pulmonary capillaries, or the membrane separating them, gas transfer may become less efficient. DLCO testing helps identify these abnormalities by measuring how much carbon monoxide is transferred from inhaled air into the blood during a controlled breathing maneuver.
Although the test uses carbon monoxide rather than oxygen, the measurement provides an estimate of the lungs’ capacity for gas transfer. Carbon monoxide is used because it binds strongly to hemoglobin, allowing its uptake from the alveoli to be measured under standardized conditions.
How DLCO testing works
DLCO testing is usually performed using a specialized pulmonary function testing machine equipped with gas analyzers that measure the concentration of gases in the inhaled and exhaled samples.
The commonly used single-breath technique involves the following steps:
- The patient is instructed to breathe normally before beginning the test.
- They exhale to a specified lung volume, usually close to residual volume.
- The patient inhales a test gas mixture containing a small, controlled concentration of carbon monoxide and an inert tracer gas.
- They hold their breath for approximately 10 seconds, allowing the carbon monoxide to move from the alveoli into the pulmonary capillary blood.
- The patient then exhales, and the machine analyzes the collected gas sample.
- The system compares the concentration of carbon monoxide in the inhaled and exhaled samples to estimate how much gas has been absorbed.
- The machine calculates the diffusion capacity and displays the result for clinical interpretation.
The inert tracer gas helps the machine estimate the volume of gas participating in the test and account for dilution of the inhaled mixture. The amount of carbon monoxide that disappears from the alveolar gas during the breath-holding period provides information about its transfer into the blood.
Factors that influence diffusion capacity
Several physiological and pathological factors influence DLCO results. Understanding these factors helps healthcare professionals interpret measurements correctly and recognize why diffusion capacity may be reduced or increased.
- Alveolar surface area: A large surface area allows more efficient gas exchange. Conditions such as emphysema destroy alveolar walls, reducing the surface area available for diffusion and potentially lowering DLCO.
- Thickness of the alveolar-capillary membrane: Gas must cross a thin barrier to move from the alveoli into the bloodstream. Diseases that cause inflammation, scarring, or thickening of this membrane can impair diffusion. Pulmonary fibrosis is an important example.
- Pulmonary capillary blood volume: The amount of blood flowing through the pulmonary capillaries influences the uptake of carbon monoxide. Conditions that reduce pulmonary capillary blood volume may lower diffusion capacity.
- Hemoglobin concentration: Carbon monoxide binds to hemoglobin in red blood cells. Patients with anemia may demonstrate reduced DLCO because less hemoglobin is available to bind the gas, even when the lung tissue itself is not significantly damaged.
- Smoking and carboxyhemoglobin levels: Recent smoking can increase carbon monoxide already present in the blood, potentially affecting DLCO measurements. This is one reason appropriate preparation and accurate clinical information are important before testing.
Conditions evaluated through DLCO testing
DLCO testing is particularly useful when healthcare providers suspect that a respiratory condition is affecting the alveolar-capillary membrane, pulmonary circulation, or available surface area for gas exchange.
Examples include:
1. Emphysema: Destruction of alveolar walls reduces the surface area available for gas exchange. Consequently, patients may demonstrate reduced diffusion capacity, particularly when emphysema is extensive.
2. Pulmonary fibrosis: Fibrotic changes thicken and distort the alveolar-capillary membrane, making gas transfer less efficient. DLCO may be reduced even in the earlier stages of some interstitial lung diseases.
3. Pulmonary vascular diseases: Conditions such as pulmonary arterial hypertension may reduce the effective pulmonary capillary blood volume available for gas exchange, resulting in reduced diffusion capacity.
4. Anemia: Reduced hemoglobin concentration can lower measured DLCO because fewer binding sites are available for carbon monoxide. The result may require adjustment for hemoglobin concentration to support accurate interpretation.
5. Interstitial lung diseases: These conditions affect the lung tissue and may interfere with the movement of gases across the alveolar-capillary membrane. DLCO testing helps evaluate the physiological impact of the disease.
DLCO may also be increased in certain circumstances, including some patients with asthma, polycythemia, or pulmonary hemorrhage. Therefore, a high result should also be interpreted in the context of the patient’s clinical condition rather than automatically considered evidence of normal lung function.
Clinical importance of diffusion capacity measurements
DLCO testing provides information that cannot be obtained from spirometry or ordinary lung volume measurements alone. A patient may have relatively preserved airflow and lung volumes but still demonstrate impaired gas transfer.
For example, a patient with early pulmonary fibrosis may present with shortness of breath during physical activity. Spirometry may show relatively preserved airflow, and lung volume measurements may demonstrate only mild restriction. However, DLCO testing may reveal a significant reduction in diffusion capacity, indicating impaired transfer of gases across the alveolar-capillary membrane.
Similarly, a patient with emphysema may demonstrate obstructive spirometry findings, increased residual volume, and reduced DLCO. When these results are considered together, they provide a more complete understanding of the underlying respiratory impairment.
It is important to recognize that DLCO does not directly measure oxygen saturation or the amount of oxygen delivered to body tissues. Instead, it estimates the lungs’ ability to transfer carbon monoxide under standardized testing conditions. Healthcare professionals interpret this measurement alongside hemoglobin concentration, lung volumes, spirometry, and the patient’s clinical presentation.
Complete Pulmonary Function Test
A complete pulmonary function test is a comprehensive respiratory assessment that combines several individual pulmonary function tests to evaluate different aspects of lung performance. Rather than examining airflow alone, it provides information about expiratory function, lung capacity, air retention, and the efficiency of gas exchange. It is commonly requested when a patient requires a more detailed evaluation of respiratory function than basic spirometry can provide.
A complete pulmonary function test generally includes three major assessments:
1. Spirometry: Evaluates airflow and the volume of air inhaled and exhaled during controlled breathing maneuvers. It measures parameters such as FEV1, FVC, and the FEV1/FVC ratio, helping identify obstructive ventilatory abnormalities.
2. Lung volume testing: Measures the different compartments of air within the lungs, including residual volume, functional residual capacity, and total lung capacity. These measurements help identify air trapping, pulmonary hyperinflation, and restrictive ventilatory defects. Body plethysmography and gas dilution techniques may be used, depending on the equipment available.
3. DLCO testing: Evaluates the ability of gases to move from the alveoli into the pulmonary bloodstream. It provides information about diffusion capacity and helps identify abnormalities associated with emphysema, pulmonary fibrosis, pulmonary vascular disease, and other conditions affecting gas exchange.
When these assessments are combined, they provide a more complete picture of respiratory physiology than any single test can offer.
What a complete pulmonary function test evaluates
The primary objective is to determine how effectively different parts of the respiratory system perform their functions. The combined measurements help healthcare providers identify whether abnormalities involve airflow, lung expansion, air retention, or gas transfer.
For example:
- Spirometry evaluates whether air moves freely through the airways or whether expiratory airflow is obstructed.
- Lung volume testing determines whether the lungs can accommodate an appropriate amount of air and whether excessive air remains after expiration.
- DLCO testing assesses whether gases can move efficiently across the alveolar-capillary membrane into the bloodstream.
These findings are particularly important because respiratory diseases do not always affect the same physiological processes. COPD may cause airflow obstruction and air trapping, while pulmonary fibrosis may reduce lung capacity and impair diffusion. A complete pulmonary function test helps distinguish these patterns and identify whether more than one abnormality is present.
When a complete pulmonary function test is indicated
Healthcare providers may order a complete pulmonary function test when symptoms, clinical findings, or initial investigations suggest that a more detailed assessment of lung function is necessary.
Common indications include:
- Unexplained shortness of breath: Patients experiencing persistent breathlessness may require comprehensive testing to investigate abnormalities involving airflow, lung volume, or gas exchange.
- Suspected restrictive lung disease: When spirometry demonstrates reduced FVC, lung volume testing can establish whether total lung capacity is also reduced, supporting a restrictive ventilatory defect.
- Assessment of COPD and emphysema: Combining spirometry, lung volume measurements, and DLCO testing helps evaluate airflow obstruction, air trapping, hyperinflation, and impaired diffusion.
- Investigation of pulmonary fibrosis: A complete assessment can identify reduced lung capacity and impaired diffusion associated with fibrotic changes in the lung tissue.
- Unexplained abnormalities on initial spirometry: When basic testing does not adequately explain a patient’s symptoms, additional measurements can provide further physiological information.
- Monitoring respiratory disease: Repeated testing may help assess changes in lung function and evaluate the effects of treatment over time.
- Preoperative assessment in selected patients: Comprehensive testing may be requested when detailed information about respiratory function is relevant to evaluating surgical risk or planning treatment.
How a complete pulmonary function test is performed
The procedure is usually conducted in a specialized pulmonary function laboratory using a full pulmonary function testing machine equipped with the necessary measurement modules. Although the exact sequence varies depending on the facility and testing protocol, the assessment generally involves the following stages:
1. Patient assessment and preparation: Before testing, the healthcare professional reviews the patient’s medical history, respiratory symptoms, current medications, smoking history, and other relevant clinical information. The patient receives instructions about the breathing maneuvers and any medication restrictions required for the specific test.
2. Spirometry: The patient performs controlled breathing maneuvers through a mouthpiece connected to the PFT machine. The equipment records airflow and expiratory volumes, including FEV1 and FVC. If bronchodilator responsiveness testing is required, spirometry may be repeated after administration of the prescribed medication.
3. Lung volume measurement: The patient undergoes additional testing to determine absolute lung volumes. This may involve sitting inside a body box for plethysmography or breathing through a specialized circuit for gas dilution or washout measurements.
4. Diffusion capacity assessment: The patient performs the single-breath DLCO maneuver by inhaling a controlled gas mixture, holding their breath briefly, and exhaling into the testing system. The machine analyzes the gas sample to estimate diffusion capacity.
5. Result recording and quality assessment: The testing software processes the measurements, generates graphs, and compares the results with appropriate reference values. The healthcare professional reviews the quality of the maneuvers and determines whether the measurements are suitable for interpretation.
A complete pulmonary function test may take approximately 15 to 30 minutes or longer, depending on the number of procedures performed, the patient’s ability to complete the maneuvers, and whether additional assessments are required.
Example of a complete pulmonary function test in clinical practice
Consider a patient who presents with progressive shortness of breath, a persistent cough, and reduced exercise tolerance. The healthcare provider suspects an underlying respiratory condition and orders a complete pulmonary function test to investigate the cause.
The PFT machine produces the following hypothetical findings:
| Test | Findings | Clinical significance |
|---|---|---|
| Spirometry | Reduced FEV1/FVC ratio | Suggests airflow obstruction |
| Lung volume testing | Increased residual volume and total lung capacity | Suggests air trapping and hyperinflation |
| DLCO testing | Reduced diffusion capacity | Suggests impaired gas transfer |
When considered together, these findings may support an obstructive respiratory pattern with hyperinflation and impaired diffusion, as can occur in emphysema. The healthcare provider would then integrate the results with the patient’s symptoms, examination findings, imaging, and other investigations to establish the most appropriate diagnosis.
In another patient with suspected pulmonary fibrosis, the findings may be different. Spirometry may demonstrate reduced FVC, lung volume testing may confirm reduced total lung capacity, and DLCO may reveal impaired diffusion. This combination supports a restrictive ventilatory pattern with impaired gas transfer.
These examples demonstrate why a complete pulmonary function test is valuable when investigating complex respiratory symptoms. Instead of relying on one measurement, healthcare professionals can examine several aspects of lung function and identify patterns that help guide further assessment and management.
Importance of combining different pulmonary function tests
Each pulmonary function test provides a specific type of information, and combining their findings improves the overall understanding of respiratory performance. Spirometry identifies abnormalities in airflow, lung volume testing evaluates the amount of air contained in the lungs, and DLCO testing assesses the efficiency of gas transfer.
However, a complete pulmonary function test does not independently establish every respiratory diagnosis. Its findings must be interpreted in relation to the patient’s clinical presentation, medical history, and other investigations. The combination of these measurements helps healthcare providers identify physiological abnormalities, determine the need for additional diagnostic procedures, and monitor changes in respiratory function.
For nurses and other healthcare professionals, understanding the purpose of each test is important when preparing patients, explaining procedures, and communicating findings within the healthcare team. It also helps clarify why a patient may require several different assessments even when the initial complaint involves a single symptom, such as shortness of breath.
Clinical Applications of Pulmonary Function Testing
Pulmonary function testing plays an important role in evaluating respiratory health because it provides objective measurements of how effectively the lungs move air, maintain adequate volumes, and transfer gases into the bloodstream. Although symptoms such as coughing, wheezing, chest tightness, and shortness of breath can suggest respiratory disease, they do not always reveal the specific physiological problem affecting the patient. Pulmonary function tests help clarify whether symptoms are associated with airflow obstruction, reduced lung expansion, impaired gas exchange, or a combination of abnormalities.
A PFT machine enables healthcare professionals to obtain measurements that support the assessment of both acute and chronic respiratory conditions. Depending on the clinical question, testing may involve spirometry, lung volume measurements, DLCO testing, or a complete pulmonary function test. These assessments are useful in diagnosing and characterizing conditions such as asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, emphysema, and other disorders affecting the airways, lung tissue, or pulmonary circulation.
The clinical value of pulmonary function testing extends beyond identifying abnormalities during an initial examination. Test results can help determine the severity of physiological impairment, guide further investigations, establish a baseline before treatment, and monitor changes in lung function over time. When interpreted alongside a patient’s symptoms, medical history, physical examination, and other diagnostic findings, pulmonary function measurements contribute to more informed decisions about respiratory care.
Assessment of Respiratory Symptoms and Lung Diseases
Pulmonary function testing is commonly requested when a patient presents with respiratory symptoms that may indicate impaired lung function. These symptoms include persistent coughing, wheezing, shortness of breath, chest tightness, excessive mucus production, and reduced exercise tolerance. Although these complaints may occur in several respiratory conditions, the underlying physiological changes can differ considerably. For example, a patient with asthma may experience intermittent narrowing of the airways, while a patient with pulmonary fibrosis may have difficulty expanding the lungs because of stiffened lung tissue. Pulmonary function tests help distinguish these patterns by measuring airflow, lung capacity, and gas transfer.
Evaluating shortness of breath and exercise intolerance
Shortness of breath, also called dyspnea, is one of the most common reasons for ordering a pulmonary function test. It may occur when the airways are narrowed, the lungs cannot expand adequately, or oxygen transfer from the alveoli into the bloodstream is impaired. Cardiovascular conditions, anemia, physical deconditioning, and other non-respiratory problems can also cause breathlessness. Therefore, pulmonary function testing helps determine whether an abnormality in respiratory physiology may be contributing to the patient’s symptoms.
Spirometry is often an initial investigation because it measures how much air a patient can forcibly exhale and how quickly the air leaves the lungs. A reduced FEV1/FVC ratio may indicate an obstructive pattern, suggesting that airflow is limited during expiration. A reduced forced vital capacity (FVC), on the other hand, may raise suspicion of reduced lung expansion or air trapping. However, a low FVC alone does not confirm restrictive lung disease. Additional lung volume measurements, particularly total lung capacity (TLC), are needed to establish whether true restriction is present.
For example, consider a patient who reports progressive breathlessness when walking uphill or climbing stairs. Spirometry may reveal a reduced FVC with a relatively preserved FEV1/FVC ratio. This finding may suggest a restrictive pattern, but it could also result from incomplete exhalation or air trapping. A complete pulmonary function test can provide further information. If TLC is below the lower limit of normal, the findings support a restrictive ventilatory impairment. If TLC is normal or elevated, the reduced FVC may have another explanation.
Investigating persistent cough and wheezing
Persistent coughing and wheezing may indicate conditions involving airway inflammation, narrowing, or excessive mucus production. Asthma is an important consideration, particularly when symptoms occur intermittently, worsen at night, or are triggered by exercise, allergens, respiratory infections, or environmental irritants. COPD may also cause chronic cough, wheezing, and increased mucus production, particularly in people with a history of tobacco smoking or exposure to harmful airborne particles.
Spirometry helps assess whether these symptoms are associated with airflow obstruction. During testing, the patient performs a forced expiratory maneuver through a mouthpiece connected to a spirometer. The machine records measurements such as FEV1, FVC, and the FEV1/FVC ratio. A reduced ratio below the appropriate lower limit of normal indicates an obstructive ventilatory pattern, although the clinical context is still needed to identify its cause.
When asthma is suspected but initial spirometry is normal, additional assessment may be necessary. Because asthma is characterized by variable airflow limitation, lung function can be normal between episodes. A healthcare provider may therefore request repeat spirometry when symptoms are present, pre- and post-bronchodilator testing, or a bronchial challenge test when clinically appropriate. A normal result on one occasion does not automatically exclude asthma.
Identifying restrictive and obstructive lung disorders
One of the major applications of pulmonary function testing is distinguishing obstructive from restrictive ventilatory patterns. These patterns describe different types of physiological impairment and can help guide further diagnostic investigations.
- Obstructive ventilatory impairment: This occurs when airflow out of the lungs is limited, commonly because of narrowed or damaged airways. It is associated with conditions such as asthma, COPD, and bronchiectasis. Spirometry typically demonstrates a reduced FEV1/FVC ratio. Depending on the condition and its severity, the patient may also have increased residual volume (RV) because air becomes trapped in the lungs during expiration.
- Restrictive ventilatory impairment: This occurs when the lungs cannot expand to their expected volume. It may result from diseases affecting the lung tissue, such as pulmonary fibrosis, or from conditions affecting the chest wall, respiratory muscles, or the space available for lung expansion. A reduced TLC confirms a restrictive ventilatory defect. Spirometry may show reduced FVC, but lung volume testing is required to confirm the pattern.
- Mixed ventilatory impairment: Some patients have both obstructive and restrictive abnormalities. In these cases, the FEV1/FVC ratio is reduced and TLC is also below the lower limit of normal. Additional measurements help determine the extent of each abnormality.
For instance, a patient with emphysema may demonstrate airflow obstruction alongside an elevated RV and TLC because damaged lung tissue and loss of elastic recoil contribute to air trapping and hyperinflation. A patient with pulmonary fibrosis may instead have reduced TLC and FVC because scarred lung tissue restricts expansion. These differences illustrate why pulmonary function testing should assess more than one measurement when the clinical presentation requires a detailed evaluation.
Assessing gas exchange and pulmonary impairment
Some respiratory diseases affect the transfer of gases across the alveolar-capillary membrane rather than causing an obvious abnormality in airflow alone. In these situations, DLCO testing provides useful additional information. DLCO, or the diffusing capacity of the lungs for carbon monoxide, estimates how effectively gas moves from the alveoli into the pulmonary capillary blood.
A reduced DLCO may occur when the surface area available for gas exchange is decreased, the alveolar-capillary membrane is thickened, or pulmonary capillary blood volume is reduced. Conditions associated with a low DLCO include emphysema, interstitial lung diseases such as pulmonary fibrosis, and certain pulmonary vascular disorders. Anemia can also reduce the measured DLCO because less hemoglobin is available to bind carbon monoxide during the test. For this reason, hemoglobin concentration may need to be considered when interpreting the result.
For example, two patients may have similar reductions in lung volume but different DLCO results. One patient with pulmonary fibrosis may have a reduced TLC and low DLCO because the disease affects both lung expansion and gas transfer. Another patient with a respiratory muscle disorder may have reduced lung volumes but a relatively preserved DLCO because the alveolar-capillary membrane itself may remain intact. The combination of measurements helps clinicians investigate the possible source of impairment.
Pulmonary function testing can also be useful when symptoms are disproportionate to findings from an initial examination. A patient may report significant breathlessness despite relatively preserved spirometry. In such circumstances, lung volume testing, DLCO assessment, exercise testing, or cardiovascular investigations may be considered to explore other explanations. The results do not establish every cause of breathlessness, but they help determine which physiological systems require further evaluation.
Pulmonary Function Testing in COPD and Asthma
COPD and asthma are two major respiratory conditions in which pulmonary function testing is particularly valuable. Both can cause wheezing, coughing, chest tightness, and difficulty breathing, and both may involve airflow limitation. However, they differ in their underlying mechanisms, typical patterns of disease progression, and response to treatment. Pulmonary function testing helps identify airflow abnormalities, assess their severity, and evaluate changes following appropriate interventions.
Role of pulmonary function testing in COPD
Chronic obstructive pulmonary disease is a progressive respiratory condition characterized by persistent airflow obstruction that is not fully reversible. It commonly includes features of chronic bronchitis, emphysema, or both. Chronic exposure to tobacco smoke, occupational dust, indoor air pollution, and other harmful particles can contribute to airway inflammation, structural damage, and loss of normal lung elasticity.
In COPD, narrowing of the small airways and destruction of alveolar structures make it difficult for air to leave the lungs during expiration. Some patients develop air trapping, in which air remains in the lungs after exhalation. This can cause lung hyperinflation, increase the work of breathing, and make physical activity increasingly difficult.
Spirometry is essential for demonstrating persistent airflow obstruction in a patient being evaluated for COPD. The FEV1/FVC ratio is measured after bronchodilator administration, and a post-bronchodilator ratio below 0.70 is commonly used in COPD diagnostic criteria. However, this fixed threshold should be interpreted in the context of the patient’s age, clinical history, symptoms, and applicable guidelines. The lower limit of normal can also be useful, particularly because the expected FEV1/FVC ratio changes with age.
Once airflow obstruction is established, FEV1 expressed as a percentage of its predicted value can help classify the degree of airflow limitation. Predicted values are estimated using reference equations that account for relevant characteristics, including age, height, and sex. The result is compared with the expected range for an appropriate reference population rather than interpreted as an isolated number.
For example, a patient with a long history of smoking may present with persistent cough, sputum production, and progressive shortness of breath. Spirometry may show an FEV1/FVC ratio of 0.58 after bronchodilator administration, indicating persistent airflow obstruction under the commonly used fixed-ratio criterion. A reduced FEV1 may indicate more substantial airflow limitation. Additional lung volume measurements may reveal an increased RV or TLC, suggesting air trapping or hyperinflation.
A complete pulmonary function test can provide further information about the type of physiological impairment associated with COPD. Lung volume testing may demonstrate increased residual volume and functional residual capacity, while DLCO may be reduced in patients with emphysema because destruction of alveolar walls decreases the surface area available for gas exchange. A low DLCO is not present in every person with COPD, so it should be interpreted alongside the other findings.
Pulmonary function testing also helps distinguish COPD from other conditions that can produce similar symptoms. For example, a patient with chronic wheezing may have asthma, COPD, or features of both. A history of symptom variability, exposure to risk factors, bronchodilator response, and the overall pattern of lung function results help guide clinical assessment. No single measurement should be used in isolation to make this distinction.
Role of pulmonary function testing in asthma
Asthma is a chronic inflammatory airway disease characterized by variable respiratory symptoms and variable expiratory airflow limitation. The airways may become inflamed, swollen, and unusually responsive to triggers, resulting in episodes of bronchoconstriction. During an exacerbation, the patient may experience wheezing, coughing, chest tightness, and shortness of breath. Between episodes, lung function may return close to normal, particularly in people with well-controlled asthma.
Spirometry is commonly used to demonstrate variable airflow limitation. A patient may have a reduced FEV1 and FEV1/FVC ratio during symptomatic periods, reflecting difficulty expelling air through narrowed airways. However, because asthma symptoms and airflow obstruction fluctuate, spirometry can sometimes be normal when the patient is not experiencing symptoms.
Bronchodilator responsiveness testing is useful when evaluating suspected asthma. The patient performs baseline spirometry, receives an inhaled bronchodilator as directed by the testing protocol, and repeats the breathing maneuvers after an appropriate interval. The healthcare professional then compares the pre- and post-bronchodilator measurements to determine whether airflow has improved.
A significant improvement in FEV1 or FVC supports the presence of variable airflow limitation. Under commonly used adult interpretive criteria, an increase in FEV1 or FVC of more than 10% of the predicted value is considered a significant bronchodilator response in the current ERS/ATS interpretive standard. Other clinical guidelines and testing protocols may use different criteria. A positive response supports the assessment of asthma but does not independently establish the diagnosis, while the absence of a significant response during one test does not exclude it.
For example, a patient who experiences intermittent wheezing after exposure to dust may have normal spirometry during an asymptomatic appointment. If symptoms are present during a later assessment, repeat spirometry may reveal reduced expiratory airflow. After administration of a bronchodilator, FEV1 may improve substantially, supporting variable airflow limitation. The healthcare provider considers these findings together with the patient’s symptom pattern, medical history, and other relevant investigations.
When initial spirometry does not demonstrate airflow variability but clinical suspicion remains high, additional tests may be considered. These can include serial peak expiratory flow monitoring or bronchial challenge testing. Such investigations help identify variable airway narrowing that may not be apparent during a single pulmonary function test.
Distinguishing COPD from asthma
Although COPD and asthma can both produce obstructive patterns on spirometry, pulmonary function testing helps characterize their differences. Asthma often involves variable airflow limitation, which may improve significantly after bronchodilator administration or with appropriate treatment. COPD is generally associated with persistent airflow obstruction, although some patients may also demonstrate a measurable bronchodilator response.
The distinction is not always straightforward. Some people with asthma develop persistent airflow limitation over time, while patients with COPD may experience symptomatic fluctuations. A bronchodilator response can occur in either condition, so it should not be treated as a stand-alone test for distinguishing them.
| Feature | Asthma | COPD |
|---|---|---|
| Typical airflow pattern | Variable expiratory airflow limitation | Persistent airflow obstruction |
| Symptom pattern | Often varies over time and with triggers | Commonly persistent or progressively worsening |
| Spirometry | May be normal between episodes; obstruction may improve after bronchodilator | Post-bronchodilator FEV1/FVC is commonly reduced |
| Bronchodilator response | May show significant improvement | May improve, but obstruction often remains |
| Lung volumes | May show air trapping during periods of obstruction | May show increased RV and hyperinflation |
| DLCO | Often normal or sometimes elevated | May be reduced, particularly with emphysema |
This comparison describes common patterns rather than absolute rules. Clinical history, examination, exposure history, imaging, and other investigations remain important when distinguishing between the two conditions.
Using pulmonary function results to guide clinical management
In both COPD and asthma, pulmonary function testing provides information that can support treatment decisions. In asthma, measurements may help establish the degree of airflow limitation and assess whether lung function improves following treatment. In COPD, spirometry helps characterize persistent obstruction, while lung volume and diffusion measurements may provide additional information about hyperinflation and gas-transfer impairment.
The results should not be used as the sole basis for selecting medication or determining treatment intensity. Asthma management also depends on symptom frequency, exacerbation history, medication use, and risk of future attacks. COPD management considers symptoms, exacerbation history, oxygenation, comorbidities, and other clinical factors in addition to spirometric findings.
For nurses and other healthcare professionals, understanding these differences supports effective patient education and monitoring. Patients may need guidance on attending scheduled pulmonary function tests, following preparation instructions, using prescribed inhaled medications correctly, and reporting changes in symptoms. Accurate documentation of symptoms and treatment history also helps clinicians interpret changes in lung function over time.
Monitoring Disease Progression and Treatment Response
Pulmonary function testing is not limited to the initial investigation of respiratory symptoms. It is also used to monitor the course of chronic lung diseases, assess response to treatment, and identify changes that may require further clinical evaluation. Repeated measurements allow healthcare professionals to compare a patient’s current respiratory function with previous results and determine whether lung performance has remained stable, improved, or deteriorated.
A baseline pulmonary function test is particularly useful when a patient is first diagnosed with a chronic respiratory condition or begins treatment that may affect lung function. Later measurements can be compared with this baseline, provided that testing is performed using appropriate procedures and the results are interpreted with consideration of expected biological and technical variability.
Tracking changes in lung function over time
Chronic respiratory diseases can produce gradual or fluctuating changes in lung function. Serial spirometry provides a practical way to monitor airflow limitation by comparing FEV1, FVC, and the FEV1/FVC ratio across different testing dates. In patients with COPD, a sustained decline in FEV1 may indicate worsening airflow limitation, although the rate of change varies considerably between individuals. In asthma, measurements may fluctuate as airway inflammation and bronchoconstriction change over time.
Lung volume measurements can also be repeated when a condition is expected to affect lung capacity or cause air trapping. For example, a patient with progressive pulmonary fibrosis may demonstrate a gradual decline in FVC and TLC as lung tissue becomes increasingly stiff and less able to expand. A patient with COPD may show changes in RV and TLC that reflect the degree of air trapping and hyperinflation.
DLCO testing is particularly useful when monitoring diseases that affect the alveolar-capillary membrane or pulmonary circulation. A declining diffusion capacity may indicate worsening impairment in gas transfer, although the result can also be influenced by factors such as anemia, smoking-related carbon monoxide exposure, and changes in hemoglobin concentration. These factors should be considered before attributing a change in DLCO to disease progression.
For example, a patient with interstitial lung disease may undergo pulmonary function testing at regular intervals. If successive results show declining FVC, TLC, and DLCO, the pattern may suggest progressive impairment in lung expansion and gas exchange. The clinician can compare these findings with symptoms, oxygen levels, imaging, and other investigations to determine whether the disease is progressing and whether the management plan needs reassessment.
Evaluating response to respiratory treatment
Pulmonary function tests can help determine whether treatment is associated with measurable improvement in respiratory function. The type of measurement used depends on the condition being treated and the expected physiological response.
In asthma, spirometry may demonstrate improvement in FEV1 after bronchodilator treatment. Repeated testing over a longer period may also help assess whether lung function has improved with anti-inflammatory therapy and whether airflow limitation is becoming better controlled. However, symptom control, exacerbation frequency, and medication requirements must also be considered because a patient may feel better without showing a large change in spirometric measurements.
In COPD, treatment may include bronchodilators, inhaled medications for selected patients, pulmonary rehabilitation, smoking cessation support, and other interventions based on clinical assessment. Follow-up spirometry can help document lung function, but symptomatic improvement does not always produce a substantial increase in FEV1. For instance, a patient may report less breathlessness and improved exercise tolerance after starting long-acting bronchodilator therapy even when the spirometry results change only modestly. This may occur because treatment can reduce dynamic hyperinflation and improve breathing efficiency without reversing the underlying structural damage.
In patients with pulmonary fibrosis, serial FVC and DLCO measurements may help evaluate changes following disease-specific treatment. Stabilization of lung function may be clinically meaningful in a progressive condition, even when measurements do not return to normal. Treatment response should therefore be judged against the expected course of the disease rather than assuming that successful management always produces a substantial increase in lung capacity.
Identifying deterioration and the need for further assessment
A meaningful decline in pulmonary function can alert healthcare professionals to possible disease progression, a new respiratory problem, or an inadequate response to treatment. However, an unexpected change should not automatically be interpreted as deterioration. Poor patient effort, incorrect technique, equipment problems, acute respiratory infection, recent exacerbation, or differences in testing conditions can affect the results.
When a follow-up test shows a substantial change, the healthcare team may review the patient’s symptoms, medication adherence, recent illnesses, smoking or occupational exposures, and previous test quality. Repeat testing may be appropriate if the result is inconsistent with the clinical presentation or appears technically unreliable. Additional investigations, such as chest imaging, oxygenation assessment, exercise testing, or specialist evaluation, may be required depending on the suspected cause.
For example, a patient with previously stable COPD may show a sudden reduction in FEV1 during a follow-up appointment. Before concluding that the disease has progressed, the healthcare professional should consider whether the patient has recently experienced an exacerbation, has difficulty following the testing instructions, or has developed another condition affecting breathing. Comparing the current result with earlier high-quality measurements helps determine whether the change is likely to represent a genuine clinical development.
Supporting long-term respiratory care and patient management
Regular pulmonary function testing can support long-term care by providing objective information that complements symptom assessment and physical examination. It can help clinicians identify trends, evaluate the effects of treatment, and determine whether additional respiratory assessment is necessary. The frequency of testing depends on the patient’s diagnosis, clinical stability, treatment plan, and applicable clinical guidelines. Not every patient requires testing at the same intervals, and repeating a test too frequently may not provide useful additional information.
Nurses contribute to this process by helping patients understand the purpose of follow-up testing, reinforcing preparation instructions, documenting relevant symptoms, and communicating concerns to the healthcare team. They may also help identify factors that could affect test performance, such as fatigue, acute illness, difficulty understanding instructions, or problems maintaining a proper seal around the mouthpiece. During and after testing, patient comfort and safety should remain priorities.
It is also important to recognize that pulmonary function measurements are only one part of respiratory monitoring. A patient with chronic lung disease may have stable spirometry but worsening breathlessness due to anemia, heart disease, infection, or reduced physical conditioning. Conversely, a measurable decline in lung function may occur before the patient notices a major change in symptoms. Combining PFT results with clinical assessment, oxygen saturation, exercise tolerance, imaging, and other relevant findings provides a more complete understanding of the patient’s condition.
Overall, pulmonary function testing supports the assessment and ongoing management of respiratory diseases by providing measurable evidence of airflow, lung capacity, and gas-transfer function. When performed consistently and interpreted in the context of the patient’s clinical condition, these measurements help healthcare professionals recognize abnormalities, monitor disease progression, and evaluate treatment response.## Clinical Applications of Pulmonary Function Testing
Pulmonary function testing plays an important role in evaluating respiratory health because it provides objective measurements of how effectively the lungs move air, maintain adequate volumes, and transfer gases into the bloodstream. Although symptoms such as coughing, wheezing, chest tightness, and shortness of breath can suggest respiratory disease, they do not always reveal the specific physiological problem affecting the patient. Pulmonary function tests help clarify whether symptoms are associated with airflow obstruction, reduced lung expansion, impaired gas exchange, or a combination of abnormalities.
A PFT machine enables healthcare professionals to obtain measurements that support the assessment of both acute and chronic respiratory conditions. Depending on the clinical question, testing may involve spirometry, lung volume measurements, DLCO testing, or a complete pulmonary function test. These assessments are useful in diagnosing and characterizing conditions such as asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, emphysema, and other disorders affecting the airways, lung tissue, or pulmonary circulation.
The clinical value of pulmonary function testing extends beyond identifying abnormalities during an initial examination. Test results can help determine the severity of physiological impairment, guide further investigations, establish a baseline before treatment, and monitor changes in lung function over time. When interpreted alongside a patient’s symptoms, medical history, physical examination, and other diagnostic findings, pulmonary function measurements contribute to more informed decisions about respiratory care.
Assessment of Respiratory Symptoms and Lung Diseases
Pulmonary function testing is commonly requested when a patient presents with respiratory symptoms that may indicate impaired lung function. These symptoms include persistent coughing, wheezing, shortness of breath, chest tightness, excessive mucus production, and reduced exercise tolerance. Although these complaints may occur in several respiratory conditions, the underlying physiological changes can differ considerably. For example, a patient with asthma may experience intermittent narrowing of the airways, while a patient with pulmonary fibrosis may have difficulty expanding the lungs because of stiffened lung tissue. Pulmonary function tests help distinguish these patterns by measuring airflow, lung capacity, and gas transfer.
Evaluating shortness of breath and exercise intolerance
Shortness of breath, also called dyspnea, is one of the most common reasons for ordering a pulmonary function test. It may occur when the airways are narrowed, the lungs cannot expand adequately, or oxygen transfer from the alveoli into the bloodstream is impaired. Cardiovascular conditions, anemia, physical deconditioning, and other non-respiratory problems can also cause breathlessness. Therefore, pulmonary function testing helps determine whether an abnormality in respiratory physiology may be contributing to the patient’s symptoms.
Spirometry is often an initial investigation because it measures how much air a patient can forcibly exhale and how quickly the air leaves the lungs. A reduced FEV1/FVC ratio may indicate an obstructive pattern, suggesting that airflow is limited during expiration. A reduced forced vital capacity (FVC), on the other hand, may raise suspicion of reduced lung expansion or air trapping. However, a low FVC alone does not confirm restrictive lung disease. Additional lung volume measurements, particularly total lung capacity (TLC), are needed to establish whether true restriction is present.
For example, consider a patient who reports progressive breathlessness when walking uphill or climbing stairs. Spirometry may reveal a reduced FVC with a relatively preserved FEV1/FVC ratio. This finding may suggest a restrictive pattern, but it could also result from incomplete exhalation or air trapping. A complete pulmonary function test can provide further information. If TLC is below the lower limit of normal, the findings support a restrictive ventilatory impairment. If TLC is normal or elevated, the reduced FVC may have another explanation.
Investigating persistent cough and wheezing
Persistent coughing and wheezing may indicate conditions involving airway inflammation, narrowing, or excessive mucus production. Asthma is an important consideration, particularly when symptoms occur intermittently, worsen at night, or are triggered by exercise, allergens, respiratory infections, or environmental irritants. COPD may also cause chronic cough, wheezing, and increased mucus production, particularly in people with a history of tobacco smoking or exposure to harmful airborne particles.
Spirometry helps assess whether these symptoms are associated with airflow obstruction. During testing, the patient performs a forced expiratory maneuver through a mouthpiece connected to a spirometer. The machine records measurements such as FEV1, FVC, and the FEV1/FVC ratio. A reduced ratio below the appropriate lower limit of normal indicates an obstructive ventilatory pattern, although the clinical context is still needed to identify its cause.
When asthma is suspected but initial spirometry is normal, additional assessment may be necessary. Because asthma is characterized by variable airflow limitation, lung function can be normal between episodes. A healthcare provider may therefore request repeat spirometry when symptoms are present, pre- and post-bronchodilator testing, or a bronchial challenge test when clinically appropriate. A normal result on one occasion does not automatically exclude asthma.
Identifying restrictive and obstructive lung disorders
One of the major applications of pulmonary function testing is distinguishing obstructive from restrictive ventilatory patterns. These patterns describe different types of physiological impairment and can help guide further diagnostic investigations.
- Obstructive ventilatory impairment: This occurs when airflow out of the lungs is limited, commonly because of narrowed or damaged airways. It is associated with conditions such as asthma, COPD, and bronchiectasis. Spirometry typically demonstrates a reduced FEV1/FVC ratio. Depending on the condition and its severity, the patient may also have increased residual volume (RV) because air becomes trapped in the lungs during expiration.
- Restrictive ventilatory impairment: This occurs when the lungs cannot expand to their expected volume. It may result from diseases affecting the lung tissue, such as pulmonary fibrosis, or from conditions affecting the chest wall, respiratory muscles, or the space available for lung expansion. A reduced TLC confirms a restrictive ventilatory defect. Spirometry may show reduced FVC, but lung volume testing is required to confirm the pattern.
- Mixed ventilatory impairment: Some patients have both obstructive and restrictive abnormalities. In these cases, the FEV1/FVC ratio is reduced and TLC is also below the lower limit of normal. Additional measurements help determine the extent of each abnormality.
For instance, a patient with emphysema may demonstrate airflow obstruction alongside an elevated RV and TLC because damaged lung tissue and loss of elastic recoil contribute to air trapping and hyperinflation. A patient with pulmonary fibrosis may instead have reduced TLC and FVC because scarred lung tissue restricts expansion. These differences illustrate why pulmonary function testing should assess more than one measurement when the clinical presentation requires a detailed evaluation.
Assessing gas exchange and pulmonary impairment
Some respiratory diseases affect the transfer of gases across the alveolar-capillary membrane rather than causing an obvious abnormality in airflow alone. In these situations, DLCO testing provides useful additional information. DLCO, or the diffusing capacity of the lungs for carbon monoxide, estimates how effectively gas moves from the alveoli into the pulmonary capillary blood.
A reduced DLCO may occur when the surface area available for gas exchange is decreased, the alveolar-capillary membrane is thickened, or pulmonary capillary blood volume is reduced. Conditions associated with a low DLCO include emphysema, interstitial lung diseases such as pulmonary fibrosis, and certain pulmonary vascular disorders. Anemia can also reduce the measured DLCO because less hemoglobin is available to bind carbon monoxide during the test. For this reason, hemoglobin concentration may need to be considered when interpreting the result.
For example, two patients may have similar reductions in lung volume but different DLCO results. One patient with pulmonary fibrosis may have a reduced TLC and low DLCO because the disease affects both lung expansion and gas transfer. Another patient with a respiratory muscle disorder may have reduced lung volumes but a relatively preserved DLCO because the alveolar-capillary membrane itself may remain intact. The combination of measurements helps clinicians investigate the possible source of impairment.
Pulmonary function testing can also be useful when symptoms are disproportionate to findings from an initial examination. A patient may report significant breathlessness despite relatively preserved spirometry. In such circumstances, lung volume testing, DLCO assessment, exercise testing, or cardiovascular investigations may be considered to explore other explanations. The results do not establish every cause of breathlessness, but they help determine which physiological systems require further evaluation.

Pulmonary Function Testing in COPD and Asthma
COPD and asthma are two major respiratory conditions in which pulmonary function testing is particularly valuable. Both can cause wheezing, coughing, chest tightness, and difficulty breathing, and both may involve airflow limitation. However, they differ in their underlying mechanisms, typical patterns of disease progression, and response to treatment. Pulmonary function testing helps identify airflow abnormalities, assess their severity, and evaluate changes following appropriate interventions.
Role of pulmonary function testing in COPD
Chronic obstructive pulmonary disease is a progressive respiratory condition characterized by persistent airflow obstruction that is not fully reversible. It commonly includes features of chronic bronchitis, emphysema, or both. Chronic exposure to tobacco smoke, occupational dust, indoor air pollution, and other harmful particles can contribute to airway inflammation, structural damage, and loss of normal lung elasticity.
In COPD, narrowing of the small airways and destruction of alveolar structures make it difficult for air to leave the lungs during expiration. Some patients develop air trapping, in which air remains in the lungs after exhalation. This can cause lung hyperinflation, increase the work of breathing, and make physical activity increasingly difficult.
Spirometry is essential for demonstrating persistent airflow obstruction in a patient being evaluated for COPD. The FEV1/FVC ratio is measured after bronchodilator administration, and a post-bronchodilator ratio below 0.70 is commonly used in COPD diagnostic criteria. However, this fixed threshold should be interpreted in the context of the patient’s age, clinical history, symptoms, and applicable guidelines. The lower limit of normal can also be useful, particularly because the expected FEV1/FVC ratio changes with age.
Once airflow obstruction is established, FEV1 expressed as a percentage of its predicted value can help classify the degree of airflow limitation. Predicted values are estimated using reference equations that account for relevant characteristics, including age, height, and sex. The result is compared with the expected range for an appropriate reference population rather than interpreted as an isolated number.
For example, a patient with a long history of smoking may present with persistent cough, sputum production, and progressive shortness of breath. Spirometry may show an FEV1/FVC ratio of 0.58 after bronchodilator administration, indicating persistent airflow obstruction under the commonly used fixed-ratio criterion. A reduced FEV1 may indicate more substantial airflow limitation. Additional lung volume measurements may reveal an increased RV or TLC, suggesting air trapping or hyperinflation.
A complete pulmonary function test can provide further information about the type of physiological impairment associated with COPD. Lung volume testing may demonstrate increased residual volume and functional residual capacity, while DLCO may be reduced in patients with emphysema because destruction of alveolar walls decreases the surface area available for gas exchange. A low DLCO is not present in every person with COPD, so it should be interpreted alongside the other findings.
Pulmonary function testing also helps distinguish COPD from other conditions that can produce similar symptoms. For example, a patient with chronic wheezing may have asthma, COPD, or features of both. A history of symptom variability, exposure to risk factors, bronchodilator response, and the overall pattern of lung function results help guide clinical assessment. No single measurement should be used in isolation to make this distinction.
Role of pulmonary function testing in asthma
Asthma is a chronic inflammatory airway disease characterized by variable respiratory symptoms and variable expiratory airflow limitation. The airways may become inflamed, swollen, and unusually responsive to triggers, resulting in episodes of bronchoconstriction. During an exacerbation, the patient may experience wheezing, coughing, chest tightness, and shortness of breath. Between episodes, lung function may return close to normal, particularly in people with well-controlled asthma.
Spirometry is commonly used to demonstrate variable airflow limitation. A patient may have a reduced FEV1 and FEV1/FVC ratio during symptomatic periods, reflecting difficulty expelling air through narrowed airways. However, because asthma symptoms and airflow obstruction fluctuate, spirometry can sometimes be normal when the patient is not experiencing symptoms.
Bronchodilator responsiveness testing is useful when evaluating suspected asthma. The patient performs baseline spirometry, receives an inhaled bronchodilator as directed by the testing protocol, and repeats the breathing maneuvers after an appropriate interval. The healthcare professional then compares the pre- and post-bronchodilator measurements to determine whether airflow has improved.
A significant improvement in FEV1 or FVC supports the presence of variable airflow limitation. The criteria used to define a significant response can differ between clinical guidelines and interpretive standards. For example, asthma guidelines commonly consider both the magnitude of improvement and the change relative to the patient’s baseline measurement. A positive response supports the assessment of asthma but does not independently establish the diagnosis, while the absence of a significant response during one test does not exclude it.
For example, a patient who experiences intermittent wheezing after exposure to dust may have normal spirometry during an asymptomatic appointment. If symptoms are present during a later assessment, repeat spirometry may reveal reduced expiratory airflow. After administration of a bronchodilator, FEV1 may improve substantially, supporting variable airflow limitation. The healthcare provider considers these findings together with the patient’s symptom pattern, medical history, and other relevant investigations.
When initial spirometry does not demonstrate airflow variability but clinical suspicion remains high, additional tests may be considered. These can include serial peak expiratory flow monitoring or bronchial challenge testing. Such investigations help identify variable airway narrowing that may not be apparent during a single pulmonary function test.
Distinguishing COPD from asthma
Although COPD and asthma can both produce obstructive patterns on spirometry, pulmonary function testing helps characterize their differences. Asthma often involves variable airflow limitation, which may improve significantly after bronchodilator administration or with appropriate treatment. COPD is generally associated with persistent airflow obstruction, although some patients may also demonstrate a measurable bronchodilator response.
The distinction is not always straightforward. Some people with asthma develop persistent airflow limitation over time, while patients with COPD may experience symptomatic fluctuations. A bronchodilator response can occur in either condition, so it should not be treated as a stand-alone test for distinguishing them.
| Feature | Asthma | COPD |
|---|---|---|
| Typical airflow pattern | Variable expiratory airflow limitation | Persistent airflow obstruction |
| Symptom pattern | Often varies over time and with triggers | Commonly persistent or progressively worsening |
| Spirometry | May be normal between episodes; obstruction may improve after bronchodilator | Post-bronchodilator FEV1/FVC is commonly reduced |
| Bronchodilator response | May show significant improvement | May improve, but obstruction often remains |
| Lung volumes | May show air trapping during periods of obstruction | May show increased RV and hyperinflation |
| DLCO | Often normal or sometimes elevated | May be reduced, particularly with emphysema |
This comparison describes common patterns rather than absolute rules. Clinical history, examination, exposure history, imaging, and other investigations remain important when distinguishing between the two conditions.
Using pulmonary function results to guide clinical management
In both COPD and asthma, pulmonary function testing provides information that can support treatment decisions. In asthma, measurements may help establish the degree of airflow limitation and assess whether lung function improves following treatment. In COPD, spirometry helps characterize persistent obstruction, while lung volume and diffusion measurements may provide additional information about hyperinflation and gas-transfer impairment.
The results should not be used as the sole basis for selecting medication or determining treatment intensity. Asthma management also depends on symptom frequency, exacerbation history, medication use, and risk of future attacks. COPD management considers symptoms, exacerbation history, oxygenation, comorbidities, and other clinical factors in addition to spirometric findings.
For nurses and other healthcare professionals, understanding these differences supports effective patient education and monitoring. Patients may need guidance on attending scheduled pulmonary function tests, following preparation instructions, using prescribed inhaled medications correctly, and reporting changes in symptoms. Accurate documentation of symptoms and treatment history also helps clinicians interpret changes in lung function over time.
Monitoring Disease Progression and Treatment Response
Pulmonary function testing is not limited to the initial investigation of respiratory symptoms. It is also used to monitor the course of chronic lung diseases, assess response to treatment, and identify changes that may require further clinical evaluation. Repeated measurements allow healthcare professionals to compare a patient’s current respiratory function with previous results and determine whether lung performance has remained stable, improved, or deteriorated.
A baseline pulmonary function test is particularly useful when a patient is first diagnosed with a chronic respiratory condition or begins treatment that may affect lung function. Later measurements can be compared with this baseline, provided that testing is performed using appropriate procedures and the results are interpreted with consideration of expected biological and technical variability.
Tracking changes in lung function over time
Chronic respiratory diseases can produce gradual or fluctuating changes in lung function. Serial spirometry provides a practical way to monitor airflow limitation by comparing FEV1, FVC, and the FEV1/FVC ratio across different testing dates. In patients with COPD, a sustained decline in FEV1 may indicate worsening airflow limitation, although the rate of change varies considerably between individuals. In asthma, measurements may fluctuate as airway inflammation and bronchoconstriction change over time.
Lung volume measurements can also be repeated when a condition is expected to affect lung capacity or cause air trapping. For example, a patient with progressive pulmonary fibrosis may demonstrate a gradual decline in FVC and TLC as lung tissue becomes increasingly stiff and less able to expand. A patient with COPD may show changes in RV and TLC that reflect the degree of air trapping and hyperinflation.
DLCO testing is particularly useful when monitoring diseases that affect the alveolar-capillary membrane or pulmonary circulation. A declining diffusion capacity may indicate worsening impairment in gas transfer, although the result can also be influenced by factors such as anemia, smoking-related carbon monoxide exposure, and changes in hemoglobin concentration. These factors should be considered before attributing a change in DLCO to disease progression.
For example, a patient with interstitial lung disease may undergo pulmonary function testing at regular intervals. If successive results show declining FVC, TLC, and DLCO, the pattern may suggest progressive impairment in lung expansion and gas exchange. The clinician can compare these findings with symptoms, oxygen levels, imaging, and other investigations to determine whether the disease is progressing and whether the management plan needs reassessment.
Evaluating response to respiratory treatment
Pulmonary function tests can help determine whether treatment is associated with measurable improvement in respiratory function. The type of measurement used depends on the condition being treated and the expected physiological response.
In asthma, spirometry may demonstrate improvement in FEV1 after bronchodilator treatment. Repeated testing over a longer period may also help assess whether lung function has improved with anti-inflammatory therapy and whether airflow limitation is becoming better controlled. However, symptom control, exacerbation frequency, and medication requirements must also be considered because a patient may feel better without showing a large change in spirometric measurements.
In COPD, treatment may include bronchodilators, inhaled medications for selected patients, pulmonary rehabilitation, smoking cessation support, and other interventions based on clinical assessment. Follow-up spirometry can help document lung function, but symptomatic improvement does not always produce a substantial increase in FEV1. For instance, a patient may report less breathlessness and improved exercise tolerance after starting long-acting bronchodilator therapy even when the spirometry results change only modestly. This may occur because treatment can reduce dynamic hyperinflation and improve breathing efficiency without reversing the underlying structural damage.
In patients with pulmonary fibrosis, serial FVC and DLCO measurements may help evaluate changes following disease-specific treatment. Stabilization of lung function may be clinically meaningful in a progressive condition, even when measurements do not return to normal. Treatment response should therefore be judged against the expected course of the disease rather than assuming that successful management always produces a substantial increase in lung capacity.
Identifying deterioration and the need for further assessment
A meaningful decline in pulmonary function can alert healthcare professionals to possible disease progression, a new respiratory problem, or an inadequate response to treatment. However, an unexpected change should not automatically be interpreted as deterioration. Poor patient effort, incorrect technique, equipment problems, acute respiratory infection, recent exacerbation, or differences in testing conditions can affect the results.
When a follow-up test shows a substantial change, the healthcare team may review the patient’s symptoms, medication adherence, recent illnesses, smoking or occupational exposures, and previous test quality. Repeat testing may be appropriate if the result is inconsistent with the clinical presentation or appears technically unreliable. Additional investigations, such as chest imaging, oxygenation assessment, exercise testing, or specialist evaluation, may be required depending on the suspected cause.
For example, a patient with previously stable COPD may show a sudden reduction in FEV1 during a follow-up appointment. Before concluding that the disease has progressed, the healthcare professional should consider whether the patient has recently experienced an exacerbation, has difficulty following the testing instructions, or has developed another condition affecting breathing. Comparing the current result with earlier high-quality measurements helps determine whether the change is likely to represent a genuine clinical development.
Supporting long-term respiratory care and patient management
Regular pulmonary function testing can support long-term care by providing objective information that complements symptom assessment and physical examination. It can help clinicians identify trends, evaluate the effects of treatment, and determine whether additional respiratory assessment is necessary. The frequency of testing depends on the patient’s diagnosis, clinical stability, treatment plan, and applicable clinical guidelines. Not every patient requires testing at the same intervals, and repeating a test too frequently may not provide useful additional information.
Nurses contribute to this process by helping patients understand the purpose of follow-up testing, reinforcing preparation instructions, documenting relevant symptoms, and communicating concerns to the healthcare team. They may also help identify factors that could affect test performance, such as fatigue, acute illness, difficulty understanding instructions, or problems maintaining a proper seal around the mouthpiece. During and after testing, patient comfort and safety should remain priorities.
It is also important to recognize that pulmonary function measurements are only one part of respiratory monitoring. A patient with chronic lung disease may have stable spirometry but worsening breathlessness due to anemia, heart disease, infection, or reduced physical conditioning. Conversely, a measurable decline in lung function may occur before the patient notices a major change in symptoms. Combining PFT results with clinical assessment, oxygen saturation, exercise tolerance, imaging, and other relevant findings provides a more complete understanding of the patient’s condition.
Overall, pulmonary function testing supports the assessment and ongoing management of respiratory diseases by providing measurable evidence of airflow, lung capacity, and gas-transfer function. When performed consistently and interpreted in the context of the patient’s clinical condition, these measurements help healthcare professionals recognize abnormalities, monitor disease progression, and evaluate treatment response.
PFT Testing Procedure
Accurate pulmonary function testing depends on more than the capabilities of the equipment. Patient preparation, correct positioning, proper breathing technique, and adherence to standardized procedures all influence the reliability of the measurements. Even a well-maintained PFT machine may produce misleading results if the patient does not understand the instructions, fails to maintain a proper seal around the mouthpiece, or performs the breathing maneuvers inconsistently.
The testing procedure generally involves reviewing the patient’s medical history, explaining the assessment, checking relevant preparation requirements, and performing the selected pulmonary function tests under controlled conditions. Depending on the clinical indication, the assessment may include spirometry, lung volume measurements, DLCO testing, or a complete pulmonary function test. Each procedure has specific instructions, but all require cooperation between the patient and the healthcare professional conducting the examination.
For nurses and other healthcare professionals, understanding the testing process is important for preparing patients, recognizing potential safety concerns, supporting correct technique, and helping ensure that the results are suitable for clinical interpretation. The following sections explain the main stages of PFT testing, from preparation to infection prevention and patient safety.
Patient Preparation Before Testing
Proper patient preparation is essential because several factors can influence respiratory measurements, including recent physical activity, smoking, medication use, food intake, posture, and the patient’s ability to follow instructions. Preparing the patient correctly helps reduce avoidable variations and improves the reliability of measurements obtained using a PFT machine. It also allows healthcare professionals to identify conditions that may make testing difficult, uncomfortable, or potentially unsafe.
Preparation begins before the appointment. Patients should receive clear instructions about activities to avoid, medications that may need to be withheld, and what to expect during the examination. The exact requirements depend on the type of pulmonary function test being performed and the clinical reason for ordering it. For example, the preparation for routine spirometry may differ from that required for bronchodilator responsiveness testing, bronchial challenge testing, or a complete pulmonary function test.
Reviewing the patient’s medical history and clinical condition
Before testing begins, the healthcare professional should review the patient’s medical history, current symptoms, previous respiratory diagnoses, medication use, and the reason for the investigation. This information helps determine whether the patient can safely perform the required breathing maneuvers and whether any special arrangements are necessary.
Relevant information may include:
- Respiratory history: Previous diagnoses of asthma, COPD, pulmonary fibrosis, bronchiectasis, or other lung conditions should be documented. The healthcare professional should also ask about recent respiratory infections, persistent coughing, wheezing, and episodes of breathlessness.
- Cardiovascular history: Conditions such as unstable angina, recent myocardial infarction, uncontrolled hypertension, or significant cardiac disease may require additional assessment before testing because forceful respiratory maneuvers can temporarily increase pressure within the chest and cardiovascular system.
- Recent surgery or injury: Recent eye, chest, abdominal, or brain surgery may affect the patient’s ability to perform forceful expiratory maneuvers safely. Recent pneumothorax, significant rib injuries, or other conditions affected by changes in intrathoracic pressure should also be considered.
- Neurological and physical limitations: Patients with weakness, cognitive impairment, facial abnormalities, or difficulty understanding instructions may require additional assistance or modified testing arrangements.
- Medication history: The type, dose, frequency, and timing of respiratory medications should be recorded, particularly bronchodilators, because they can influence airflow measurements.
These factors do not automatically prevent pulmonary function testing. Instead, they help the referring clinician and testing professional assess potential risks and determine whether the procedure should proceed, be modified, or be postponed. If a patient develops severe breathlessness, chest pain, dizziness, or other concerning symptoms before testing, the healthcare team should assess the situation before continuing.
Providing instructions about food, smoking, alcohol, and physical activity
Patients should receive practical instructions about activities that may temporarily affect lung function. Although specific recommendations vary between laboratories and testing protocols, several general precautions are commonly used.
- Eating: Patients are generally advised to avoid a large meal for approximately two hours before testing. A full stomach can make deep inhalation and forceful expiration uncomfortable and may interfere with respiratory maneuvers.
- Smoking and vaping: Smoking, vaping, and exposure to other inhaled irritants should be avoided before testing, commonly for at least one hour. Some facilities recommend avoiding smoking throughout the day because smoke can cause temporary airway irritation or bronchoconstriction.
- Physical activity: Vigorous exercise should generally be avoided for at least 30–60 minutes before testing. Exercise may temporarily change breathing patterns and can trigger bronchoconstriction in susceptible individuals.
- Alcohol and intoxicating substances: Alcohol and other intoxicants should be avoided for the period specified by the testing facility. These substances can affect coordination, concentration, and the patient’s ability to follow breathing instructions.
- Clothing: Patients should wear loose-fitting clothing that allows the chest and abdomen to expand freely. Tight belts, restrictive garments, and clothing that compresses the torso can interfere with deep inspiration.
For example, a patient who arrives immediately after strenuous exercise may have an elevated respiratory rate and may find it difficult to perform controlled breathing maneuvers. Similarly, a patient who has just eaten a heavy meal may experience abdominal discomfort when asked to inhale deeply. Recording these circumstances helps the testing professional decide whether the procedure can proceed or whether a short delay would improve test conditions.
Reviewing medication use and bronchodilator instructions
Medication preparation is particularly important when spirometry is being performed to assess bronchodilator responsiveness. Bronchodilators relax airway smooth muscle and improve airflow in patients with reversible or partially reversible airway narrowing. If a patient uses these medications shortly before testing, the baseline measurements may already reflect their effects, making it more difficult to evaluate the degree of improvement after an additional dose.
Depending on the clinical question, the healthcare provider may instruct the patient to withhold selected bronchodilators before the appointment. The withholding period varies according to the medication, its duration of action, and the laboratory protocol. Short-acting bronchodilators may require a shorter withholding period than long-acting medications.
However, patients should never be instructed to stop prescribed respiratory medication independently. Withholding medication may be inappropriate or unsafe for some individuals, particularly those with poorly controlled asthma or significant respiratory symptoms. The ordering clinician should determine whether medication should be withheld, and the testing professional should document which medications were taken and when.
The distinction between diagnostic testing and treatment monitoring is important. When the purpose is to assess the patient’s untreated or baseline airflow limitation, selected bronchodilators may be withheld if clinically appropriate. When the objective is to evaluate lung function while the patient is receiving their usual treatment, medication may be continued. Consistency in medication conditions is also important when comparing results from different appointments.
Checking patient identity, measurements, and baseline observations
Before the test begins, the healthcare professional should confirm the patient’s identity using the facility’s identification procedures and verify the test requested. Patient characteristics such as age, height, and sex are important because the PFT machine uses appropriate reference equations to compare measured values with expected lung function.
Height should generally be measured without shoes, and weight may also be recorded, particularly when required by the testing system or clinical protocol. If the patient cannot stand safely, an appropriate alternative method of estimating height may be used according to laboratory standards. Accurate demographic information matters because an incorrect height or other input can produce misleading predicted values and affect interpretation.
Baseline observations may include respiratory rate, heart rate, oxygen saturation, blood pressure, and the presence of respiratory distress, depending on the patient’s condition and local procedure. The healthcare professional should also note symptoms such as coughing, wheezing, chest discomfort, cyanosis, or unusual fatigue.
The patient should be informed about what each part of the test involves. This is particularly important because some procedures require repeated forceful breathing, while others involve sitting inside a body plethysmography chamber or briefly holding the breath during DLCO testing. Explaining the procedure in advance can reduce anxiety and improve cooperation.
Preparing patients with special needs
Some patients require additional support to complete pulmonary function testing successfully. Children, older adults, individuals with physical disabilities, and patients with cognitive or communication difficulties may need adapted instructions or assistance.
For children, the testing professional may use demonstrations, visual instructions, or age-appropriate encouragement to help them understand the breathing maneuvers. Young children may not be able to perform conventional spirometry reliably, so alternative methods may be considered depending on their age and clinical indication.
Patients with hearing impairment may benefit from written instructions or visual demonstrations. Those with language barriers may require a qualified interpreter to ensure that they understand the procedure. Patients who use wheelchairs or have limited mobility may need assistance with positioning or entering a body plethysmography chamber.
For example, a patient with severe arthritis may struggle to maintain the required posture or grip the mouthpiece comfortably. The testing professional may need to adjust the seating arrangement, provide physical support, or select an appropriate alternative testing method. These adjustments should preserve patient safety without compromising the quality of the measurements.
Step-by-Step Testing and Proper Mouthpiece Use
The exact procedure depends on the type of pulmonary function test ordered and the capabilities of the equipment. However, most assessments follow a structured sequence involving patient positioning, instruction, equipment preparation, breathing maneuvers, repeated measurements, and review of test quality. Proper technique is essential because inaccurate performance can affect measurements such as FEV1, FVC, lung volume, and diffusion capacity.
Step 1: Positioning the patient and preparing the equipment
The patient is positioned according to the requirements of the test. For routine spirometry, testing is commonly performed while the patient is seated upright in a chair with armrests, with the feet supported and the head in a neutral or slightly elevated position. Seated testing provides stability and reduces the risk of injury if the patient becomes dizzy during forceful breathing.
The healthcare professional prepares the PFT machine by checking that it is functioning correctly, confirming that the appropriate test has been selected, and ensuring that the required accessories are available. These may include a mouthpiece, nose clip, disposable filter, tubing, and other components specified by the equipment manufacturer.
The operator also checks that the system has undergone the required calibration or verification procedures. This is important because the accuracy of airflow and volume measurements depends on the proper functioning of the sensors and measurement system.
Before beginning, the patient should be given time to settle into the correct position. If the patient is anxious or has difficulty understanding the instructions, the testing professional should explain and demonstrate the maneuver before attaching the mouthpiece.
Step 2: Explaining and demonstrating the breathing maneuver
The patient should understand what is expected before the test begins. During spirometry, the healthcare professional explains that the patient will first inhale as deeply as possible, place the mouthpiece securely between the lips, and then exhale as forcefully and completely as instructed.
A typical explanation may involve the following instructions:
- Sit upright and relax the shoulders.
- Place the mouthpiece in the mouth, ensuring that the lips form a tight seal around it.
- Breathe in fully until the lungs are filled as much as possible.
- When instructed, blow out as hard and as quickly as possible.
- Continue exhaling until the healthcare professional tells you to stop or the lungs are adequately emptied.
- If required by the testing protocol, inhale again as deeply and rapidly as possible before removing the mouthpiece.
The healthcare professional may demonstrate the maneuver to help the patient understand the required effort. Clear verbal encouragement is also important because some patients initially exhale too gently or stop before completing the maneuver.
For example, a patient may understand that they need to breathe out but may not realize that the initial expiration must be forceful and immediate. The operator can explain that the aim is not simply to empty the lungs slowly but to produce a rapid, strong expiration that allows the machine to measure airflow accurately.
Step 3: Correct placement and use of the mouthpiece
Proper mouthpiece use is essential because air leakage can result in inaccurate measurements. The patient should place the mouthpiece beyond the lips as instructed, without biting excessively or obstructing the opening with the tongue. The lips must remain firmly closed around the mouthpiece throughout the maneuver.
A nose clip is commonly used during spirometry to prevent air from escaping through the nose. If the patient exhales through the nose rather than through the mouthpiece, the PFT machine may record less air than the patient actually expels. This can affect the measured FVC and other spirometric values.
The testing professional should check that:
- The mouthpiece is correctly positioned and not obstructed by the tongue or teeth.
- The patient’s lips form a complete seal around the mouthpiece.
- The nose clip is correctly fitted when required.
- The patient does not remove the mouthpiece before completing the maneuver.
- The patient does not cough, hesitate, or interrupt expiration during the critical part of the measurement.
A common technical problem occurs when a patient allows air to escape around the mouthpiece during forceful expiration. This may cause the recorded volume to be lower than the actual amount of air expelled. Another problem occurs when the patient bites down on the mouthpiece or places the tongue over its opening, restricting airflow. The operator should correct these problems before repeating the maneuver.
Step 4: Performing spirometry
Once the patient understands the instructions and the mouthpiece is correctly positioned, the operator begins the spirometry procedure. The patient takes a complete inspiration, followed by a rapid and forceful expiration into the spirometer. The machine records the volume of air expelled and the rate at which it flows over time.
Important measurements include:
- Forced vital capacity (FVC): The total volume of air forcibly exhaled after a full inspiration.
- Forced expiratory volume in one second (FEV1): The volume of air exhaled during the first second of the forced expiratory maneuver.
- FEV1/FVC ratio: The proportion of the total forced vital capacity exhaled during the first second.
- Peak expiratory flow (PEF): The highest airflow achieved during forced expiration.
The patient may be asked to repeat the maneuver several times to establish whether the results are reproducible. Repetition is important because one attempt may be affected by poor effort, coughing, hesitation, or incomplete inspiration. The operator evaluates the quality of each attempt and selects acceptable measurements according to standardized criteria.
For example, if a patient produces an FEV1 of 1.8 L during the first attempt and 2.2 L during the next, the difference may indicate that the initial effort was inadequate. The testing professional may provide additional instruction and repeat the maneuver until acceptable and reproducible results are obtained or the patient can no longer continue safely.
Step 5: Performing bronchodilator responsiveness testing when indicated
Some spirometry procedures include measurements before and after administration of a bronchodilator. This is commonly performed when evaluating suspected asthma or assessing the degree of airflow improvement following airway-relaxing medication.
The initial spirometry measurements are obtained before the medication is administered. The patient then receives the prescribed bronchodilator through an inhaler, spacer, or other appropriate delivery device. After the required waiting period, spirometry is repeated using the same technique.
The healthcare professional compares the pre- and post-bronchodilator measurements to determine whether FEV1 or FVC has increased significantly according to the applicable interpretive criteria.
For instance, a patient with suspected asthma may initially demonstrate reduced expiratory airflow. After receiving a bronchodilator, the patient may produce a higher FEV1, suggesting that airway narrowing has improved. This finding supports the presence of variable airflow limitation, although it must be interpreted alongside symptoms and other clinical information.
Step 6: Performing lung volume measurements
If the patient requires lung volume testing, the procedure may involve body plethysmography or a gas dilution or washout technique. The method used depends on the clinical indication, the equipment available, and the patient’s ability to perform the procedure.
During body plethysmography, the patient sits inside a sealed transparent chamber and breathes through a mouthpiece connected to the measurement system. The operator provides instructions for normal breathing and the specific breathing maneuvers required by the test. The equipment records pressure and airflow changes that are used to calculate lung volumes, including functional residual capacity and other static measurements.
For example, a patient with suspected COPD may undergo lung volume testing to determine whether air trapping is contributing to breathlessness. An elevated residual volume may indicate that a significant amount of air remains in the lungs after expiration. This information can complement spirometry by showing abnormalities that basic airflow measurements cannot fully describe.
Step 7: Performing DLCO testing when indicated
DLCO testing evaluates the ability of gas to move from the alveoli into the pulmonary capillary blood. The patient breathes through a mouthpiece connected to the PFT machine and follows instructions to inhale a test gas containing a small concentration of carbon monoxide and an inert tracer gas.
The typical single-breath procedure involves:
- Exhaling to the level specified by the testing protocol, usually near residual volume.
- Inhaling the test gas rapidly and deeply toward total lung capacity.
- Holding the breath for approximately 10 seconds, according to the protocol.
- Exhaling as instructed so that the equipment can collect and analyze an appropriate sample of alveolar gas.
The machine uses the change in carbon monoxide concentration, together with the tracer gas measurement, to calculate the diffusing capacity. The test does not directly measure oxygen transfer but provides an estimate of the lungs’ ability to transfer gas into the bloodstream.
The patient must follow the instructions carefully because incomplete inspiration, an inadequate breath-hold, or air leakage can affect the result. The testing professional should also consider relevant factors such as smoking history, recent smoking, and hemoglobin concentration when interpreting the measurement.
Step 8: Reviewing test quality and documenting results
After the required procedures have been completed, the operator reviews the recorded measurements and checks whether the maneuvers meet acceptable quality standards. This includes evaluating the flow-volume and volume-time curves, identifying possible technical errors, and determining whether repeated measurements are sufficiently consistent.
Common problems include:
- Coughing during the first second of forced expiration.
- Hesitation before beginning expiration.
- Incomplete inhalation before the maneuver.
- Early termination of expiration.
- Air leakage around the mouthpiece.
- Obstruction of the mouthpiece by the tongue.
- Poor patient effort or inconsistent technique.
If a maneuver is technically unacceptable, it may need to be repeated when safe and appropriate. However, the patient should not be pressured to continue if they develop significant dizziness, chest pain, severe breathlessness, or other concerning symptoms.
The final report should include the relevant measurements, test quality information, and any factors that may affect interpretation. Results are generally compared with appropriate reference values and interpreted using standardized criteria. The clinician then considers the findings alongside the patient’s symptoms, medical history, examination, and other investigations.
Infection Control and Patient Safety
Infection control is a fundamental part of pulmonary function testing because patients breathe directly through equipment that may come into contact with respiratory secretions. Forceful expiration can also generate respiratory droplets and aerosols, creating a potential risk of exposure for healthcare professionals and other people in the testing area. Appropriate precautions help prevent cross-contamination, protect staff and patients, and maintain a safe testing environment.
Patient safety is equally important because pulmonary function testing involves repeated respiratory maneuvers that can temporarily cause dizziness, coughing, fatigue, or breathlessness. Some patients may have underlying cardiovascular or respiratory conditions that require additional monitoring. Therefore, the testing professional must understand both the infection prevention requirements and the potential physiological effects of the procedure.
Hand hygiene and use of personal protective equipment
Hand hygiene should be performed before and after contact with each patient and after handling potentially contaminated equipment. Healthcare professionals may use an approved alcohol-based hand rub or wash their hands with soap and water according to infection prevention protocols.
Gloves should be worn when handling used mouthpieces, filters, tubing, or other equipment contaminated with respiratory secretions. They may also be necessary when there is a risk of contact with blood or other body fluids. If gloves are used, they should be changed between patients, and hand hygiene must still be performed before putting on and after removing them.
Additional personal protective equipment, such as masks, eye protection, gowns, or respirators, may be required depending on the patient’s infection status, the nature of the procedure, local infection prevention policies, and the assessed risk of aerosol exposure. Facilities should follow current respiratory infection precautions and occupational safety guidance.
Use of disposable mouthpieces and filters
Disposable mouthpieces and in-line bacterial and viral filters are commonly used during spirometry to reduce contamination of the equipment. The filter is placed between the patient’s mouthpiece and the measurement system, helping prevent respiratory secretions and microorganisms from entering the internal components of the PFT machine.
Each patient should receive a new disposable mouthpiece and filter when required by the equipment design and facility protocol. Nose clips and other single-use accessories should also be replaced between patients. Used disposable components should be discarded appropriately after the examination rather than reused.
For example, if a spirometry station is used to test several patients during a clinic session, the operator should replace the disposable filter and mouthpiece after each patient’s test. Reusing these components without an approved reprocessing procedure could expose subsequent patients to respiratory secretions from the previous individual.
The filter must also be compatible with the equipment because it can affect airflow resistance and measurement accuracy. Healthcare professionals should use accessories approved by the manufacturer and follow the recommended procedures for their installation and replacement.
Cleaning and disinfection of reusable equipment
Not every component of a PFT system is disposable. Reusable items such as tubing, breathing valves, nose clips, sensor housings, and surfaces of the equipment may require cleaning and disinfection. The specific method depends on the material, device design, manufacturer’s instructions, and the level of contamination risk.
Cleaning removes visible dirt, mucus, and organic material, while disinfection reduces or eliminates many disease-causing microorganisms. These processes are not interchangeable. Equipment should be cleaned before disinfection when required because organic material can interfere with the effectiveness of disinfectants.
The testing facility should follow the manufacturer’s instructions regarding:
- Approved cleaning agents and disinfectants.
- Correct disinfectant concentration and contact time.
- Components that can be immersed or sterilized.
- Components that must remain dry or should not be exposed to certain chemicals.
- Replacement schedules for filters, tubing, and other accessories.
- Procedures for cleaning surfaces that patients and staff frequently touch.
Reusable components should be fully dried and stored appropriately before the next use. Improper cleaning can damage sensitive sensors, interfere with airflow measurements, or leave chemical residues that may irritate the respiratory tract.
The exterior surfaces of the PFT machine, chair, control panel, door handles, and nearby work surfaces should also be cleaned according to the facility’s infection prevention schedule. Particular attention should be given to areas frequently touched by patients during testing.
Managing respiratory droplets and aerosol exposure
Pulmonary function testing can generate respiratory droplets and aerosols, particularly during forceful expiratory maneuvers. Patients may also cough between attempts, increasing the possibility of contamination in the immediate testing environment.
To reduce exposure, testing should take place in a designated area with appropriate ventilation and sufficient space for safe patient movement. The operator should follow local recommendations regarding room ventilation, air clearance between patients when applicable, and use of protective equipment.
Patients should be instructed to cough or sneeze into a tissue or their elbow when possible and to perform hand hygiene afterward. Tissues and other contaminated materials should be discarded in the appropriate waste container. If a patient has a suspected or confirmed contagious respiratory infection, the facility should assess whether routine testing should be postponed, performed in a designated area, or conducted using additional precautions. Urgent testing decisions should be made in consultation with the clinical team.
Recognizing and managing discomfort during testing
Although pulmonary function tests are generally well tolerated, repeated forceful breathing can cause temporary symptoms. Patients may experience coughing, dizziness, light-headedness, fatigue, or shortness of breath. These effects can occur because repeated forced expiration and deep inspiration temporarily alter breathing patterns and intrathoracic pressure.
The operator should observe the patient throughout the procedure and provide rest periods between maneuvers when necessary. Patients should be encouraged to report discomfort immediately rather than trying to complete the test despite worsening symptoms.
If a patient becomes dizzy, the maneuver should be stopped and the patient allowed to rest in a safe position. If symptoms persist, the healthcare professional should assess the patient and follow the facility’s clinical escalation procedures. Testing should not resume until the patient is stable and it is appropriate to continue.
Chest pain, severe breathlessness, fainting, marked oxygen desaturation, or other concerning symptoms require prompt assessment. The testing professional should follow emergency procedures when indicated rather than treating these symptoms as routine effects of the examination.
Preventing falls and ensuring safe positioning
Patient positioning is another important safety consideration. Some patients may become light-headed after repeated forced expiratory maneuvers, while others may have poor balance, muscle weakness, or difficulty moving between testing stations.
For routine spirometry, a stable seated position is commonly preferred. Patients who are at risk of falling should not be required to stand during forceful breathing maneuvers unless the test specifically requires it and appropriate precautions are in place.
Additional assistance may be needed when a patient enters or exits a body plethysmography chamber. The operator should ensure that the patient can access the chamber safely, understands how to communicate discomfort, and knows how the door can be opened if assistance is needed. Patients with claustrophobia or mobility limitations may require additional preparation or an alternative method of measuring lung volumes.
Supplemental oxygen and other medical support equipment require particular attention during testing. For some procedures, such as body plethysmography, equipment may need to be temporarily disconnected or adjusted according to the testing protocol. This must be planned and supervised by qualified personnel; oxygen should never be withheld without appropriate clinical authorization and a safe monitoring plan.
Maintaining equipment safety and testing accuracy
Infection prevention and patient safety also depend on maintaining the PFT machine in proper working condition. Damaged tubing, faulty connections, blocked filters, inaccurate sensors, and poorly maintained valves can affect both the safety of the patient and the reliability of test results.
Before testing, the operator should inspect the equipment for visible damage, confirm that connections are secure, and ensure that the correct disposable accessories are installed. Calibration or verification checks should be completed according to the manufacturer’s instructions and the laboratory’s quality-control procedures.
If the equipment produces an unexpected error, displays inconsistent measurements, or appears to be malfunctioning, testing should be stopped until the problem has been assessed. Results obtained using equipment that has not passed the required quality checks should not be treated as reliable.
Accurate documentation is also essential. The testing record should include relevant patient preparation information, medications taken, any deviations from instructions, symptoms observed during testing, technical difficulties, and measures taken to maintain safety. This information helps clinicians interpret the findings correctly and determine whether repeat testing is necessary.
For nurses and other healthcare professionals, infection control and patient safety require continuous attention before, during, and after pulmonary function testing. Proper hand hygiene, appropriate use of disposable filters, cleaning of reusable components, safe patient positioning, and careful observation reduce avoidable risks. When these precautions are combined with clear instructions and standardized testing techniques, pulmonary function measurements are more likely to be reliable while protecting both patients and healthcare staff.
Interpretation of Pulmonary Function Test Results
Interpreting pulmonary function test results involves examining measurements of airflow, lung volume, and gas-transfer efficiency to determine how well the respiratory system is functioning. A PFT machine records physiological measurements during different breathing maneuvers, but the numbers displayed on the report do not independently establish a respiratory diagnosis. They must be evaluated in relation to the patient’s age, height, sex, symptoms, medical history, examination findings, and reason for testing.
The interpretation process generally begins with an assessment of test quality to establish whether the patient performed the required maneuvers correctly and whether the equipment produced reliable measurements. The healthcare professional then compares the recorded values with appropriate reference ranges, examines relationships between measurements, and identifies patterns that may indicate obstructive impairment, restrictive impairment, impaired gas exchange, or a combination of abnormalities.
The major measurements include forced expiratory volume in one second (FEV1), forced vital capacity (FVC), the FEV1/FVC ratio, total lung capacity (TLC), residual volume (RV), and diffusing capacity of the lungs for carbon monoxide (DLCO). Each provides different information about respiratory function. For example, spirometry can identify airflow limitation, lung volume testing can establish whether the lungs have reduced capacity or excessive retained air, and DLCO testing can help assess how effectively gases move from the alveoli into the pulmonary circulation.
Understanding these measurements is important because different lung diseases can produce similar symptoms while causing different physiological changes. A patient with COPD may have reduced expiratory airflow and increased residual volume, whereas a patient with pulmonary fibrosis may have reduced lung capacity and impaired diffusion. Correct interpretation allows healthcare professionals to recognize these patterns, determine whether additional investigations are necessary, and assess changes in respiratory function over time.
FEV1, FVC, and FEV1/FVC Measurements
FEV1, FVC, and the FEV1/FVC ratio are among the most important measurements obtained during spirometry. They provide information about the amount of air a patient can forcibly exhale and how quickly that air leaves the lungs. These values are particularly useful when assessing obstructive airway diseases such as asthma and COPD, although they can also help identify possible restrictive patterns that require further investigation.
The measurements are obtained during a forced expiratory maneuver. The patient inhales fully, places the mouthpiece securely between the lips, and exhales as forcefully and completely as possible into the spirometer. The PFT machine records airflow and exhaled volume, generating measurements that can be compared with predicted values and interpreted together.
Forced expiratory volume in one second (FEV1)
FEV1 refers to the amount of air a person can forcibly exhale during the first second of a maximal forced expiration following a full inspiration. It is an important indicator of expiratory airflow because it reflects how quickly air can move through the airways during the initial part of expiration.
In a person with normal airway function, air can generally be expelled rapidly because the airways remain sufficiently open and the lungs maintain adequate elastic recoil. However, when the airways become narrowed, inflamed, obstructed, or structurally damaged, expiration may become slower. This can reduce the volume of air expelled during the first second and produce a lower FEV1.
FEV1 is commonly expressed in liters and compared with a predicted value calculated using reference equations. These equations account for factors such as age, height, and sex, allowing the measured result to be evaluated against the expected lung function of an appropriate reference population.
For example, suppose a patient’s predicted FEV1 is 3.0 liters, but the measured value is 1.8 liters. The patient’s FEV1 is approximately 60% of the predicted value. This indicates that the volume of air expelled during the first second is below the expected value. However, FEV1 alone cannot establish the type of respiratory impairment or identify a specific disease. It must be considered alongside FVC, the FEV1/FVC ratio, and other pulmonary function measurements.
A reduced FEV1 is commonly associated with obstructive diseases such as asthma and COPD. It may also occur in restrictive lung disorders because reduced lung expansion can limit the amount of air available for expiration. Therefore, a low FEV1 does not automatically indicate airway obstruction.
In patients with COPD, FEV1 is also used to assess the degree of airflow limitation after persistent obstruction has been established. In asthma, it can help demonstrate variable airflow limitation and evaluate changes following bronchodilator administration. Repeated FEV1 measurements may also be useful when monitoring respiratory function over time.
Forced vital capacity (FVC)
Forced vital capacity is the total amount of air a person can forcibly exhale after taking the deepest possible breath. It represents the volume expelled during a complete forced expiratory maneuver, beginning from near total lung capacity and continuing toward residual volume.
FVC provides information about the volume of air that can be moved out of the lungs during forced expiration. It is influenced by lung size, the ability of the chest and respiratory muscles to expand the lungs, airway function, and the presence of air trapping.
A reduced FVC may occur in several respiratory conditions. In restrictive lung diseases, such as pulmonary fibrosis, scarring and stiffness of lung tissue limit expansion, reducing the total volume of air the lungs can hold. In obstructive diseases, severe airflow limitation may prevent the patient from emptying the lungs completely, resulting in air trapping and a reduced measured FVC.
For example, a patient with pulmonary fibrosis may have an FVC of 2.1 liters when the predicted value is 3.5 liters. This represents approximately 60% of the predicted value. The reduced measurement may suggest a restrictive pattern, particularly if the FEV1/FVC ratio is preserved or increased. However, spirometry alone cannot confirm restriction. Lung volume testing must demonstrate a reduced total lung capacity before a restrictive ventilatory defect can be established.
FVC is also useful for monitoring certain chronic respiratory conditions. A progressive reduction may indicate worsening impairment in lung expansion, particularly in patients with interstitial lung disease. However, changes must be interpreted alongside symptoms, test quality, and other measurements because poor effort or incomplete expiration can also reduce the recorded value.
FEV1/FVC ratio
The FEV1/FVC ratio expresses the proportion of the total forced vital capacity that a person exhales during the first second of the maneuver. It is calculated by dividing FEV1 by FVC and is commonly expressed as a percentage.
\[ \text{FEV1/FVC ratio}=\frac{\text{FEV1}}{\text{FVC}}\times100 \]
This ratio is particularly important because it helps distinguish obstructive airflow limitation from other patterns of respiratory impairment. When the airways are narrowed, the patient may be unable to expel a normal proportion of the total exhaled volume during the first second. Consequently, FEV1 falls disproportionately compared with FVC, producing a reduced ratio.
For example, consider a patient whose FEV1 is 1.5 liters and whose FVC is 3.0 liters:
\[ \frac{1.5}{3.0}\times100=50\% \]
The FEV1/FVC ratio is therefore 50%. If this is below the appropriate lower limit of normal, it indicates an obstructive ventilatory pattern. The finding may occur in asthma, COPD, or another condition affecting expiratory airflow. Further clinical assessment is needed to identify the underlying cause.
A preserved or increased FEV1/FVC ratio alongside a reduced FVC may suggest a restrictive pattern. However, it is important not to diagnose restriction based on this combination alone. Air trapping, incomplete expiration, respiratory muscle weakness, and suboptimal effort can also reduce FVC. A reduced TLC is required to confirm a restrictive ventilatory defect.
The ratio must be interpreted using appropriate reference values rather than relying on one percentage for every patient. The expected FEV1/FVC ratio changes with age, and a value that may be abnormal in a younger adult could be within the expected range for an older person. The lower limit of normal, commonly represented by the fifth percentile of the reference population or a z-score below approximately -1.645, helps account for these differences.
A fixed FEV1/FVC ratio below 0.70 is also commonly used in COPD diagnostic criteria after bronchodilator administration. However, this threshold serves a particular clinical purpose and should not be confused with the general reference-based approach used to interpret spirometry across different age groups.
Understanding the relationship between FEV1, FVC, and the ratio
The three measurements should be interpreted together because each provides different information about respiratory function.
| Spirometry finding | Possible interpretation | Further consideration |
|---|---|---|
| Reduced FEV1 and reduced FEV1/FVC ratio | Obstructive ventilatory impairment | Consider asthma, COPD, or another airway disorder |
| Reduced FVC with preserved or increased FEV1/FVC ratio | Possible restrictive pattern | Measure TLC to confirm restriction |
| Reduced FEV1, reduced FVC, and reduced FEV1/FVC ratio | Obstruction with reduced FVC | Assess lung volumes for air trapping or a mixed defect |
| Normal FEV1, FVC, and FEV1/FVC ratio | No spirometric abnormality demonstrated | Normal spirometry does not exclude every respiratory disease |
For instance, a patient with asthma may have a reduced FEV1 and FEV1/FVC ratio during an episode of bronchoconstriction. Following bronchodilator administration, the FEV1 may increase and the ratio may improve, suggesting variable airflow limitation. A patient with COPD may also show some improvement after a bronchodilator, but persistent airflow obstruction may remain.
In another example, a patient with suspected pulmonary fibrosis may have reduced FEV1 and FVC but a preserved ratio. This pattern raises suspicion of restriction, but a lung volume assessment is necessary to determine whether TLC is actually reduced.
Bronchodilator response and interpretation of spirometry
Bronchodilator responsiveness testing compares spirometry measurements before and after administration of a medication that relaxes airway smooth muscle. It is particularly useful when evaluating suspected asthma or determining whether airflow limitation improves following bronchodilator treatment.
The healthcare professional examines changes in FEV1 and FVC after the medication has been administered according to the testing protocol. A significant increase supports the presence of variable airflow limitation. The response should be evaluated using the relevant current interpretive standard, which may express the change relative to the patient’s predicted value rather than simply the baseline measurement.
A positive bronchodilator response does not independently confirm asthma because improvement can also occur in patients with COPD and other obstructive conditions. Similarly, the absence of a significant response during one examination does not rule out asthma, particularly when the patient is asymptomatic or has already used respiratory medication.
It is also important to distinguish between improvement in spirometric measurements and overall clinical improvement. A patient may experience less wheezing and breathlessness after treatment even when the measured FEV1 changes only slightly. Treatment effectiveness therefore requires consideration of symptoms, exacerbation frequency, medication requirements, and other clinical findings.
Lung Volume and DLCO Measurements
While spirometry measures the amount and speed of air expelled during forced breathing, it cannot directly measure every volume of air remaining in the lungs. Some air remains in the respiratory system even after a person exhales as completely as possible. This residual air is important when evaluating conditions associated with air trapping, hyperinflation, or reduced lung expansion.
Lung volume testing and DLCO assessment provide additional information that helps complete the evaluation of respiratory function. Lung volume measurements describe how much air the lungs contain during different phases of breathing, while DLCO estimates how effectively gas passes from the alveoli into the pulmonary capillary blood. These measurements are particularly useful when spirometry alone cannot explain a patient’s symptoms or establish the type of lung impairment.
Important lung volume measurements
Several lung volumes and capacities are considered when interpreting a complete pulmonary function test. Each describes a different aspect of respiratory mechanics.
- Tidal volume (TV): The amount of air inhaled or exhaled during normal, quiet breathing. It represents the volume moved into and out of the lungs during ordinary respiratory activity.
- Inspiratory reserve volume (IRV): The additional amount of air a person can inhale after completing a normal inspiration. It reflects the extra inspiratory capacity available when taking a deep breath.
- Expiratory reserve volume (ERV): The additional amount of air that can be forcibly exhaled after a normal expiration.
- Residual volume (RV): The amount of air remaining in the lungs after maximal expiration. This air cannot be expelled through ordinary or forced breathing maneuvers.
- Functional residual capacity (FRC): The volume of air remaining in the lungs at the end of a normal, passive expiration. It is calculated as the sum of expiratory reserve volume and residual volume.
- Vital capacity (VC): The maximum amount of air that can be exhaled after taking the deepest possible breath. It includes inspiratory reserve volume, tidal volume, and expiratory reserve volume.
- Total lung capacity (TLC): The total amount of air in the lungs after maximal inspiration. It includes all the measurable lung volumes, including residual volume.
The relationships between these measurements can be expressed using the following equations:
\[ FRC=ERV+RV \]
\[ TLC=VC+RV \]
\[ VC=IRV+TV+ERV \]
These relationships help explain why lung volume testing provides information that basic spirometry cannot obtain. For example, spirometry can measure vital capacity but cannot directly determine residual volume. Since residual volume contributes to both FRC and TLC, specialized lung volume techniques are needed to calculate these capacities.
Total lung capacity and the assessment of restriction
TLC is particularly important when evaluating suspected restrictive lung disease. It represents the maximum amount of air the lungs can contain following a full inspiration. When lung tissue becomes stiff, the chest wall cannot expand adequately, or respiratory muscles are unable to generate sufficient inspiratory effort, total lung capacity may fall below the expected range.
A TLC below the lower limit of normal confirms a restrictive ventilatory defect. This distinction is important because a reduced FVC on spirometry may suggest restriction but does not establish it. Air trapping, incomplete expiration, and other factors can also reduce FVC.
For example, a patient with pulmonary fibrosis may demonstrate reduced FVC and TLC because scar tissue makes the lungs less compliant and limits their ability to expand. A patient with severe respiratory muscle weakness may also have reduced TLC because the respiratory muscles cannot generate adequate force for full inspiration. Although both patients may show a restrictive pattern, the underlying causes differ.
Residual volume and air trapping
Residual volume is especially useful when evaluating obstructive respiratory diseases. It represents the air that remains in the lungs after the patient has exhaled as fully as possible. Although some residual air is normal and necessary to prevent complete collapse of the alveoli, an abnormally increased RV may indicate that the lungs are not emptying efficiently.
In conditions such as COPD and severe asthma, narrowed airways may collapse prematurely during expiration or become obstructed by inflammation and mucus. This makes it difficult for air to leave the lungs, resulting in air trapping. The residual volume may consequently increase.
For example, a patient with emphysema may have a high RV because the destruction of alveolar walls reduces elastic recoil, making it harder for the lungs to push air out during expiration. The patient may also have increased FRC and TLC, indicating hyperinflation. These changes can contribute to breathlessness because the patient begins each new breath with an excessive amount of air already remaining in the lungs.
An elevated RV/TLC ratio can provide additional evidence of air trapping. This ratio expresses the proportion of total lung capacity occupied by residual air. However, it should be interpreted using appropriate reference values and alongside the other lung volume measurements.
Functional residual capacity and lung hyperinflation
FRC represents the amount of air remaining in the lungs at the end of a normal expiration. It reflects the balance between the inward elastic recoil of the lungs and the outward recoil of the chest wall.
An increased FRC may occur in obstructive conditions associated with air trapping and hyperinflation. In COPD, for example, patients may have difficulty exhaling completely before the next breath begins. This can cause the resting lung volume to increase, making breathing more demanding and reducing the amount of additional air the patient can comfortably inhale.
A reduced FRC may occur in conditions that decrease lung compliance or limit chest expansion. Examples include severe obesity, pregnancy, certain chest wall disorders, and some restrictive lung diseases. The interpretation depends on the patient’s clinical circumstances and the other measured lung volumes.
Interpreting DLCO and diffusion capacity
DLCO stands for diffusing capacity of the lungs for carbon monoxide. It is also referred to as the transfer factor and measures how effectively carbon monoxide moves from the alveolar airspaces into the blood in the pulmonary capillaries during a standardized breathing maneuver.
Although the test uses carbon monoxide, it does not directly measure oxygen transfer. Carbon monoxide is used because it binds strongly to hemoglobin, allowing the equipment to estimate the efficiency of gas transfer across the alveolar-capillary membrane.
A normal diffusion process requires several structures and physiological factors to function effectively. These include adequate alveolar surface area, an intact alveolar-capillary membrane, sufficient pulmonary capillary blood volume, and an appropriate amount of hemoglobin available to bind the gas. An abnormality in any of these areas may affect the measured DLCO.
A reduced DLCO may occur in:
- Pulmonary fibrosis and other interstitial lung diseases: Thickening and scarring of the alveolar-capillary membrane interfere with the movement of gases into the bloodstream.
- Emphysema: Destruction of alveolar walls reduces the surface area available for gas exchange and may decrease the pulmonary capillary bed.
- Pulmonary vascular disease: Conditions that reduce blood flow through the pulmonary capillaries can impair the transfer of gas.
- Anemia: Reduced hemoglobin concentration means less hemoglobin is available to bind carbon monoxide, potentially lowering the measured DLCO.
A high DLCO can occur in some circumstances, including pulmonary hemorrhage, polycythemia, and certain patients with asthma. It should not automatically be interpreted as evidence of unusually healthy lungs because the result may reflect changes in blood volume, hemoglobin concentration, or other physiological factors.
Factors that influence DLCO interpretation
DLCO measurements can be affected by factors that are not necessarily caused by progression of lung disease. Hemoglobin concentration is particularly important because carbon monoxide binds to hemoglobin during the test. A patient with anemia may have a lower DLCO even when the lung membrane itself is relatively intact. The result may therefore require adjustment for hemoglobin.
Smoking is another important consideration. Carbon monoxide from tobacco smoke can increase carboxyhemoglobin levels, affecting the measurement. Recent smoking should be documented, and patients should follow the testing laboratory’s instructions about avoiding smoking before the examination.
Other factors include the patient’s age, altitude, inspired oxygen concentration, lung volume achieved during the maneuver, and technical quality of the breath-hold procedure. Incomplete inspiration or an inadequate breath-hold can affect the result and make interpretation less reliable.
For example, a patient with suspected pulmonary fibrosis may have a reduced DLCO because thickened lung tissue interferes with gas transfer. However, if the same patient also has significant anemia, the measured diffusion capacity may be lower than expected from the lung disease alone. Considering hemoglobin concentration helps prevent an incorrect interpretation of the severity of pulmonary impairment.
Interpreting lung volumes and DLCO together
The greatest value of lung volume and diffusion measurements often comes from examining them together rather than interpreting each result independently.
| Measurement pattern | Possible clinical significance |
|---|---|
| Reduced TLC and reduced DLCO | May occur in interstitial lung disease, including pulmonary fibrosis |
| Increased RV and increased TLC | May indicate air trapping and hyperinflation, commonly associated with COPD |
| Reduced TLC with relatively preserved DLCO | May occur in extrapulmonary restriction, such as some neuromuscular or chest wall disorders |
| Reduced DLCO with relatively preserved lung volumes | May suggest pulmonary vascular disease, early interstitial disease, anemia, or emphysema with relatively preserved volumes |
| Reduced DLCO with obstructive spirometry and increased RV | May support emphysema as a component of obstructive lung disease |
These patterns are useful for directing further assessment, but they are not specific diagnoses. Imaging, clinical history, examination findings, blood tests, and other investigations may be needed to determine the underlying condition.
Normal and Abnormal Test Findings
Pulmonary function test results are interpreted by comparing measured values with reference values that represent the expected lung function of an appropriate population. The PFT machine may display the patient’s measured values, predicted values, percentage of predicted values, and lower and upper limits of normal. Understanding these comparisons is essential because a measurement cannot be classified accurately by looking at the numerical value alone.
Normal results suggest that the measured aspects of respiratory function fall within the expected range. Abnormal results indicate that one or more measurements are outside the expected range and may reflect impaired airflow, reduced lung capacity, air trapping, or abnormal gas transfer. However, an abnormal pulmonary function test does not automatically identify a particular disease, and normal results do not exclude every respiratory condition.
Understanding predicted values and reference ranges
Predicted values are estimates of the lung function expected in a person with similar characteristics to the patient being tested. Reference equations commonly account for age, height, and sex, among other factors relevant to the selected equation. These values allow healthcare professionals to compare an individual’s measurements with those of an appropriate reference population.
For example, a measured FEV1 of 2.5 liters may be normal for one patient but reduced for another, depending on their age, height, sex, and the reference equation used. Therefore, interpreting the result as normal or abnormal based only on the number of liters would be inappropriate.
The percentage of predicted value is calculated as follows:
\[ \text{Percentage predicted}= \frac{\text{Measured value}}{\text{Predicted value}}\times100 \]
If a patient’s measured FVC is 2.4 liters and the predicted value is 3.0 liters, the percentage predicted is:
\[ \frac{2.4}{3.0}\times100=80\% \]
This indicates that the measured FVC is 80% of the predicted value. However, the percentage predicted should not be used as the only criterion for deciding whether a result is normal. Modern interpretation relies on appropriate reference limits and z-scores because the expected variability differs between measurements and patient groups.
The lower limit of normal (LLN) generally represents the fifth percentile of the reference population. A result below this limit is considered lower than expected. For many pulmonary function measurements, a z-score below approximately -1.645 indicates that the value falls below the LLN. Similarly, an upper limit of normal may be used to identify unusually high measurements.
Normal pulmonary function test findings
A normal pulmonary function test generally demonstrates measurements within their appropriate reference ranges, without evidence of significant airflow obstruction, restriction, or impaired diffusion.
Normal spirometry usually shows:
- FEV1 within the expected reference range.
- FVC within the expected reference range.
- FEV1/FVC ratio at or above the lower limit of normal.
- Acceptable and reproducible breathing maneuvers.
Normal lung volume measurements show that TLC, RV, and other measured capacities fall within their expected ranges. A normal DLCO indicates that the measured capacity for gas transfer is within the appropriate reference range after relevant adjustments have been considered.
For example, a patient undergoing pulmonary function testing because of intermittent breathlessness may have an FEV1 and FVC within expected limits, a normal FEV1/FVC ratio, normal TLC, and normal DLCO. These findings indicate that the measured aspects of lung function are preserved at the time of testing. However, they do not exclude every possible cause of breathlessness. The patient may still require assessment for cardiovascular disease, anemia, pulmonary vascular disorders, intermittent asthma, or other conditions that may not produce abnormalities during a routine PFT.
A normal result must therefore be interpreted in relation to the patient’s symptoms and the reason for testing. Some diseases may produce abnormalities only during episodes of active symptoms, while others may require specialized testing beyond routine spirometry and lung volume assessment.
Obstructive ventilatory impairment
An obstructive pattern occurs when airflow out of the lungs is limited, particularly during expiration. It is commonly identified by an FEV1/FVC ratio below the lower limit of normal. The reduced ratio indicates that FEV1 has decreased disproportionately compared with FVC.
Obstructive patterns are associated with conditions such as:
- Asthma.
- Chronic obstructive pulmonary disease.
- Bronchiectasis.
- Other diseases affecting the airways.
The degree of airflow limitation can be further assessed using FEV1 after obstruction has been established. In COPD, FEV1 percentage predicted is commonly used to classify the degree of airflow limitation under the applicable clinical framework.
Additional lung volume measurements may show increased RV, FRC, or TLC when air trapping and hyperinflation are present. DLCO may be reduced in emphysema because the destruction of alveolar walls decreases the surface area available for gas exchange. In asthma, DLCO is often preserved, although individual results can vary.
For example, a patient with COPD may have an FEV1/FVC ratio below the expected lower limit of normal, a reduced FEV1, and an elevated RV. If TLC is also increased, the findings may indicate airflow obstruction accompanied by hyperinflation. A reduced DLCO may provide additional evidence of impaired gas transfer, particularly when emphysema is suspected.
Restrictive ventilatory impairment
A restrictive ventilatory defect occurs when the total amount of air the lungs can contain is reduced. It is confirmed by a TLC below the lower limit of normal. Spirometry may suggest restriction when FVC is reduced and the FEV1/FVC ratio is preserved or increased, but lung volume testing is necessary to confirm the abnormality.
Restrictive impairment can result from diseases affecting lung tissue, such as pulmonary fibrosis, or from conditions that limit expansion of the chest and respiratory system. Examples include neuromuscular disorders, chest wall abnormalities, and some cases of severe obesity.
The pattern may involve reduced TLC, reduced FVC, and a relatively preserved FEV1/FVC ratio. DLCO may also be reduced when the disease affects the alveolar-capillary membrane. However, it may remain relatively preserved in some conditions where the restriction is caused by factors outside the lung tissue.
For instance, a patient with pulmonary fibrosis may demonstrate reduced TLC and FVC alongside a reduced DLCO. This combination suggests impaired lung expansion and gas transfer. Further assessment, including chest imaging and clinical evaluation, may help establish the underlying diagnosis.
Mixed ventilatory impairment
A mixed ventilatory defect occurs when both airflow obstruction and restriction are present. It is characterized by a reduced FEV1/FVC ratio together with a TLC below the lower limit of normal.
This distinction is important because a patient with a low FEV1/FVC ratio and reduced FVC does not necessarily have a mixed defect. Severe obstruction can cause air trapping, which reduces the amount of air that can be forcibly exhaled and produces a low FVC. Lung volume measurements are needed to determine whether TLC is also reduced.
For example, a patient with COPD and a separate interstitial lung disease may demonstrate a reduced FEV1/FVC ratio because of airway obstruction and a reduced TLC because of restricted lung expansion. This combination supports a mixed ventilatory impairment. The clinician must then investigate the contribution of each condition to the patient’s symptoms and respiratory limitations.
Abnormal lung volume and diffusion findings
Some patients have abnormal lung volume or DLCO measurements even when spirometry does not clearly demonstrate obstruction or restriction. These findings can provide important clues about respiratory disease that might otherwise remain unrecognized.
Examples include:
- Elevated RV: May indicate air trapping, particularly in obstructive airway disease.
- Elevated TLC: May indicate hyperinflation, commonly associated with emphysema or other obstructive conditions.
- Reduced TLC: Confirms restrictive ventilatory impairment when below the lower limit of normal.
- Reduced DLCO: May suggest impaired gas transfer due to interstitial lung disease, emphysema, pulmonary vascular disease, or anemia.
- Elevated DLCO: May occur in conditions such as pulmonary hemorrhage or polycythemia and in some patients with asthma.
These abnormalities should be interpreted in combination with other measurements. For example, a reduced DLCO with normal spirometry may prompt investigation for pulmonary vascular disease or early interstitial lung disease. Similarly, an increased RV in a patient with relatively preserved spirometry may suggest air trapping that requires further assessment.
Recognizing technical errors and unreliable results
Not every abnormal measurement represents a genuine change in respiratory function. Poor technique, inadequate effort, equipment problems, and inconsistent testing conditions can produce misleading results. Therefore, reviewing test quality is an essential part of interpretation.
Common technical problems include:
- Incomplete inspiration: If the patient does not inhale fully before forced expiration, FVC and FEV1 may be lower than expected.
- Early termination of expiration: Stopping too soon may reduce the recorded FVC and affect the FEV1/FVC ratio.
- Coughing: A cough during the first second of expiration can interfere with FEV1 measurement.
- Air leakage: A poor seal around the mouthpiece may result in inaccurate volume measurements.
- Hesitation: Delaying the start of forced expiration can affect the recorded expiratory measurements.
- Inconsistent effort: Different levels of effort across repeated maneuvers can reduce reproducibility.
- Incorrect patient information: Errors in height, age, or other demographic inputs can lead to inappropriate predicted values.
For example, a patient may produce a low FVC because they stop exhaling before the lungs have been adequately emptied. If this technical problem is not recognized, the result could be mistaken for a restrictive pattern. Reviewing the flow-volume curve, volume-time curve, and repeatability of the maneuvers helps determine whether the result is reliable.
The quality of lung volume and DLCO testing also matters. Incomplete inspiration, inadequate breath-holding, leaks, and other technical problems may affect these measurements. Healthcare professionals should therefore consider the quality grading and comments included in the laboratory report before drawing conclusions.
Integrating pulmonary function findings with clinical assessment
Pulmonary function test results should never be interpreted in isolation. They provide objective information about respiratory physiology but do not independently identify every disease responsible for an abnormal pattern. Clinical history, symptoms, physical examination, medication use, imaging, laboratory findings, and other investigations help establish the significance of the results.
For example, a reduced FEV1/FVC ratio may support an obstructive pattern, but the clinician must consider whether the patient has asthma, COPD, bronchiectasis, or another airway condition. A reduced TLC may confirm restriction, but it does not distinguish pulmonary fibrosis from neuromuscular weakness or chest wall disease. Similarly, a low DLCO may indicate impaired gas transfer but can occur in several pulmonary and non-pulmonary conditions.
When reviewing results, healthcare professionals should also compare current measurements with previous high-quality tests when available. A value that is abnormal but stable over several years may have a different clinical significance from a measurement that has declined substantially over a short period. Changes should be assessed against expected biological variation and the technical quality of each test.
For nurses, understanding the basic interpretation of pulmonary function measurements supports effective patient care and communication with respiratory therapists and clinicians. Nurses should be able to recognize the purpose of key measurements, understand why additional testing may be required, and identify symptoms that warrant further assessment. They should also explain to patients that pulmonary function results are one part of the overall diagnostic process rather than a complete diagnosis on their own.
A reliable interpretation combines acceptable test quality, appropriate reference values, relationships between spirometry and lung volume measurements, and the clinical context. This approach allows pulmonary function testing to provide meaningful information about airflow, lung capacity, and gas exchange while helping healthcare professionals make informed decisions about further investigation, treatment, and respiratory follow-up.
PFT Machine Selection and Maintenance
Selecting and maintaining a PFT machine requires careful consideration of clinical needs, testing capabilities, measurement accuracy, patient safety, and long-term operating costs. Pulmonary function testing equipment is used to assess different aspects of respiratory health, including airflow, lung volumes, and gas-transfer capacity. However, not every pulmonary function testing machine performs the same procedures. Some devices are designed primarily for basic spirometry, while others are comprehensive systems capable of performing spirometry, lung volume measurements, body plethysmography, and DLCO testing.
The appropriate equipment depends on the type of patients being assessed, the respiratory conditions commonly investigated, the expected testing workload, and the availability of trained personnel. A small outpatient clinic that mainly evaluates asthma and COPD may require a reliable spirometer with basic diagnostic capabilities. A specialist respiratory laboratory, on the other hand, may need a complete pulmonary function testing system that can perform several types of tests and provide more detailed information about lung function.
Equipment selection is only one part of ensuring reliable pulmonary function testing. Regular calibration or verification, preventive maintenance, appropriate cleaning, software updates, and technical support are also necessary. Poorly maintained equipment can produce inaccurate measurements, compromise patient safety, and lead to incorrect clinical conclusions. Understanding these considerations helps healthcare facilities select suitable PFT equipment and maintain its performance throughout its working life.
Essential Features of PFT Equipment
The features of a pulmonary function testing machine determine the range of respiratory assessments it can perform, the accuracy of its measurements, and how easily healthcare professionals can use it in clinical practice. When selecting equipment, healthcare facilities should consider both its immediate testing capabilities and its suitability for future clinical requirements.
A basic spirometer may be sufficient for facilities that primarily perform routine spirometry, while a respiratory laboratory may require a more advanced system capable of measuring lung volumes, diffusion capacity, and other respiratory parameters. The choice should be guided by the intended clinical applications rather than by the number of features advertised by the manufacturer.
Testing capabilities and measurement range
One of the most important considerations is the range of pulmonary function tests the equipment can perform. A facility should identify the measurements required for its patient population before selecting a particular model.
Important testing capabilities include:
- Spirometry: The equipment should accurately measure FEV1, FVC, FEV1/FVC, peak expiratory flow, and other relevant airflow parameters. These measurements are particularly important when evaluating asthma, COPD, and other conditions affecting the airways.
- Lung volume measurement: Advanced systems may measure TLC, RV, FRC, and other lung capacities. These measurements help identify restriction, air trapping, and hyperinflation that cannot be fully evaluated through basic spirometry.
- DLCO testing: A system with diffusion capacity assessment can evaluate how effectively gas moves across the alveolar-capillary membrane. This capability is useful when investigating emphysema, pulmonary fibrosis, and pulmonary vascular disorders.
- Bronchodilator responsiveness testing: The system should support comparison of spirometry measurements before and after bronchodilator administration when this assessment is required.
- Flow-volume and volume-time curves: These graphical displays allow healthcare professionals to assess breathing maneuvers, recognize technical errors, and evaluate patterns of airflow limitation.
For example, a primary healthcare facility that mainly screens patients with suspected asthma may need a reliable spirometer with pre- and post-bronchodilator testing capabilities. A specialist respiratory center assessing patients with unexplained breathlessness may require a complete pulmonary function testing system that also measures lung volumes and DLCO.
Facilities should also consider whether the equipment can accommodate additional testing modules in the future. A modular system may allow a clinic to begin with spirometry and later add lung volume or diffusion testing as its clinical services expand.
Measurement accuracy and sensor technology
A PFT machine should have reliable sensors capable of detecting changes in airflow, pressure, and gas concentration. The quality of these components directly affects the measurements displayed in the final report.
Common sensor technologies include:
- Pneumotachographs: These measure airflow by detecting pressure differences across a known resistance. The recorded flow signal is integrated over time to calculate the volume of air moved during breathing.
- Turbine sensors: These estimate airflow by measuring the rotation of a turbine or vane as air passes through the device.
- Ultrasonic sensors: These use changes in the transmission of ultrasound signals to determine airflow and calculate respiratory volumes.
- Pressure sensors: These detect pressure changes and are particularly important in body plethysmography, where pressure relationships are used to estimate lung volumes.
- Gas analyzers: These measure gas concentrations during specialized procedures such as DLCO testing.
The choice of sensor affects equipment performance, maintenance requirements, and sensitivity to environmental conditions. For example, some flow sensors are more susceptible to moisture or contamination, while others may require specific disposable components. Healthcare facilities should therefore evaluate the manufacturer’s stated accuracy, operating requirements, and recommended quality-control procedures.
Software, reporting, and data management
Modern pulmonary function testing equipment relies on software to record respiratory measurements, generate graphs, calculate predicted values, and produce reports. Good software should make it easier to perform tests, review results, identify technical errors, and compare measurements from different appointments.
Important software features include:
- Automatic calculation of FEV1, FVC, FEV1/FVC, TLC, RV, and DLCO when the corresponding tests are available.
- Flow-volume and volume-time curve displays.
- Appropriate reference equations and lower and upper limits of normal.
- Quality grading and alerts for unacceptable or poorly reproducible maneuvers.
- Pre- and post-bronchodilator comparison.
- Storage and retrieval of previous patient results.
- Generation of clear reports for clinical review.
- Data export and compatibility with electronic medical record systems where required.
Reference equations are particularly important. A pulmonary function testing system should support appropriate reference standards for the population being assessed. Incorrect demographic information or unsuitable reference equations can lead to misleading predicted values and incorrect interpretation.
For example, a patient may undergo spirometry every six months to monitor COPD. Software that stores previous results allows the healthcare professional to compare the current FEV1 and FVC with earlier measurements and identify significant changes. This is more useful than relying on a single test report without access to the patient’s previous results.
Data management should also include appropriate access controls, secure storage, backup procedures, and protection of patient confidentiality. These features are important in facilities that maintain electronic patient records or share reports with other healthcare providers.
Ease of use, portability, and patient comfort
Equipment should be practical for the environment in which it will be used. A complicated system may require extensive training and more time for each examination, while a portable device may be more suitable for bedside assessments, community clinics, or facilities with limited space.
Important design considerations include:
- A clear display that allows the operator to monitor measurements during testing.
- Simple controls and an understandable testing interface.
- Adjustable seating and suitable patient positioning arrangements.
- Accessible mouthpieces, filters, and other accessories.
- A compact design where space is limited.
- Reliable power supply and battery options where necessary.
- Easy connection to computers, printers, and patient record systems.
- Compatibility with patients who have different physical and functional needs.
Patient comfort should not be overlooked. A suitable chair, appropriately designed mouthpiece, accessible controls, and clear visual instructions can improve cooperation, particularly among older adults and patients with significant breathing difficulties.
Accessories and compatibility
A PFT machine may require several accessories to perform different tests safely and accurately. These may include mouthpieces, nose clips, bacterial and viral filters, tubing, flow sensors, calibration syringes, breathing valves, gas cylinders, and body plethysmography components.
Before purchasing equipment, facilities should establish whether these accessories are readily available and whether they are compatible with the selected model. Some manufacturers use proprietary components, meaning that replacement filters, sensors, or other consumables may need to be purchased directly from specific suppliers.
For example, a clinic may purchase an affordable spirometer but later discover that compatible disposable filters are expensive or difficult to obtain. This can increase the cost of each examination and disrupt routine testing if supplies become unavailable.
Accuracy, Calibration, and Quality Control
Accuracy is one of the most important requirements of pulmonary function testing. A PFT machine must provide measurements that closely represent the patient’s actual respiratory performance. Inaccurate results can lead to incorrect conclusions about airflow obstruction, lung capacity, or gas exchange, potentially affecting diagnosis, treatment decisions, and patient monitoring.
Equipment accuracy depends on the quality of its sensors, appropriate calibration, correct environmental measurements, proper operation, and routine quality-control procedures. Even a sophisticated pulmonary function testing machine requires regular checks to confirm that it continues to function within acceptable performance limits.
Understanding calibration and calibration verification
Calibration and calibration verification are related but different procedures.
Calibration establishes or adjusts the relationship between the signals detected by the equipment’s sensors and the actual flow, volume, or pressure being measured. It ensures that the system translates the signals generated during breathing into accurate respiratory measurements.
Calibration verification, on the other hand, checks whether the equipment continues to operate within its specified accuracy limits. It does not necessarily involve adjusting the device. Instead, it determines whether the existing calibration remains acceptable.
For example, a spirometer may be calibrated by the manufacturer before delivery. However, regular verification is still necessary to confirm that the equipment has not developed measurement errors during use. If a verification check fails, the operator must investigate the cause and follow the manufacturer’s instructions for recalibration, maintenance, or repair.
Daily spirometer calibration verification
Spirometry equipment commonly requires daily calibration verification when it is in use. A widely used method involves a calibrated 3-liter syringe, which delivers a known volume of air through the spirometer.
The operator connects the syringe to the equipment using the appropriate adapter and performs the verification according to the manufacturer’s procedure. The syringe should be discharged at different flow rates to assess whether the equipment measures volume accurately under varying airflow conditions.
Under the 2019 ATS/ERS spirometry standard, the verification process uses a 3-liter syringe across a range of flows, and the measured volume should generally remain within the specified accuracy tolerance of ±3%. The exact procedure and acceptance limits should follow the applicable technical standard and manufacturer instructions.
For example, when a 3-liter syringe is discharged through a spirometer, the displayed volume should be close to 3.0 liters and within the accepted tolerance. If the machine consistently displays a substantially different value, the operator should not proceed with routine patient testing until the problem has been investigated and corrected.
Calibration verification is particularly important when:
- The equipment is used for the first time on a testing day.
- The spirometer has been moved or transported.
- A sensor, filter, or other measurement component has been replaced.
- The equipment has undergone servicing or repair.
- Environmental conditions have changed significantly.
- Previous verification results indicate inconsistent measurements.
- The machine has displayed an error or malfunction warning.
A calibration syringe should also be inspected regularly for leaks, damage, sticking, or movement of adjustable components. A damaged syringe can produce inaccurate verification results, making it difficult to determine whether the problem lies with the syringe or the spirometer.
Environmental conditions and measurement accuracy
Environmental conditions can influence pulmonary function measurements, particularly in systems that rely on flow sensors and gas analysis. Temperature, atmospheric pressure, and humidity may affect gas volume calculations and the performance of certain components.
For example, the volume of air measured at room temperature differs from the volume that the same gas occupies when warmed to body temperature and saturated with water vapor. Pulmonary function equipment accounts for these physiological differences through appropriate corrections, including the body temperature and pressure saturated (BTPS) correction.
Incorrect entry of room temperature, atmospheric pressure, or other required environmental information may therefore affect the accuracy of calculated measurements.
Facilities should follow the manufacturer’s instructions regarding environmental monitoring and data entry. Equipment used in mobile testing environments may require particular attention because temperature and atmospheric conditions can vary more widely than in a controlled laboratory.
Quality control and reproducibility
Quality control involves routine procedures used to confirm that equipment, testing methods, and operator performance remain reliable. It goes beyond checking whether the machine powers on or displays measurements. It examines whether the complete testing process produces consistent and acceptable results.
Important quality-control activities include:
- Performing calibration verification at the recommended frequency.
- Inspecting flow sensors, tubing, connectors, and filters.
- Checking the performance of the calibration syringe.
- Reviewing test curves and measurement consistency.
- Monitoring trends in verification results.
- Confirming that software calculations and reference equations are functioning correctly.
- Documenting equipment problems, repairs, and maintenance activities.
Quality control should also include assessment of the testing process. Even when a PFT machine is functioning correctly, poorly trained operators or inconsistent patient instructions can affect the reliability of the results.
For instance, if a patient repeatedly produces spirometry measurements that vary substantially, the operator should consider whether the patient is having difficulty following instructions, whether there is a technical problem with the mouthpiece connection, or whether the equipment requires inspection.
Some laboratories also use physiological control checks involving a person with stable, reproducible lung function to monitor changes in the complete testing system over time. Such checks complement equipment verification but do not replace the required calibration procedures.
Documentation and equipment performance records
Every facility should maintain records of calibration verification, quality-control findings, repairs, software updates, and equipment servicing. These records help identify recurring problems and demonstrate that the equipment has been maintained appropriately.
A quality-control log may include:
| Record | Information to document |
|---|---|
| Calibration verification | Date, time, operator, measured values, and whether the check passed |
| Equipment inspection | Condition of sensors, tubing, connectors, and accessories |
| Maintenance | Cleaning, component replacement, adjustments, and repairs |
| Software updates | Update date, software version, and verification of relevant calculations |
| Technical problems | Error messages, suspected causes, and corrective actions |
| Servicing | Service date, technician, work performed, and confirmation of acceptable performance |
If the equipment fails a required verification check, it should be removed from clinical use until the issue has been addressed and acceptable performance has been confirmed. Continuing to test patients with equipment known to be unreliable can compromise patient care and produce misleading reports.
Cleaning and Routine Maintenance
Routine cleaning and maintenance help preserve the performance, safety, and lifespan of pulmonary function testing equipment. Because patients breathe directly through parts of the system, the equipment may become contaminated with respiratory droplets, saliva, mucus, and other secretions. In addition to preventing cross-contamination, appropriate maintenance helps protect sensitive components from moisture, blockage, and physical damage.
The cleaning procedure depends on the equipment design and the materials used in its components. A spirometer with disposable flow sensors may require different maintenance from a full pulmonary function testing system with reusable tubing, valves, gas analyzers, and a body plethysmography chamber. Facilities should follow the manufacturer’s instructions rather than applying the same cleaning method to every component.
Cleaning patient-contact components
Patient-contact components include mouthpieces, nose clips, breathing tubes, filters, and other accessories used during testing. Some are designed for single use, while others may be reusable if they can be appropriately reprocessed.
Disposable mouthpieces and filters should be replaced between patients according to the manufacturer’s recommendations and infection prevention policies. Reusable components should undergo the specified cleaning and disinfection procedure before they are used again.
Cleaning should remove visible contamination, while disinfection reduces the presence of microorganisms. The two processes are not interchangeable. Where required, reusable components should be cleaned before disinfection because mucus and other organic material can interfere with disinfectant effectiveness.
For example, a reusable breathing tube that has visible respiratory secretions should not simply be wiped on the outside and returned to service. It must undergo the approved cleaning and reprocessing procedure before being used for another patient.
Healthcare professionals should also ensure that cleaned components are adequately dried before reassembly. Residual moisture can interfere with some flow sensors, encourage microbial growth, or affect measurement performance.
Maintaining flow sensors, tubing, and connections
Flow sensors are particularly important because they detect the movement of air during respiratory maneuvers. Depending on their design, they may be sensitive to mucus, dust, moisture, or other forms of contamination.
Routine inspection should identify:
- Visible debris or secretions inside the sensor.
- Blockages in the airflow channels.
- Cracks or physical damage.
- Moisture accumulation.
- Loose or incorrectly fitted connections.
- Damaged tubing or worn seals.
- Signs of leakage around connectors.
A partially blocked sensor may restrict airflow and affect the measurements recorded by the equipment. Similarly, a leak in the tubing may cause the machine to record a smaller volume than the patient actually exhales.
Cleaning should only be performed using the methods and products approved by the manufacturer. Some sensors contain delicate components that may be damaged by immersion, excessive pressure, or unsuitable cleaning agents. If a sensor cannot be cleaned safely, replacement may be necessary.
Cleaning the exterior of the PFT machine
The external surfaces of the equipment should be cleaned regularly, particularly those frequently touched by patients and operators. These include the control panel, display screen, buttons, handles, chair, and nearby work surfaces.
The selected cleaning agent should be compatible with the equipment’s materials. Excessive liquid should not be allowed to enter electrical connections, sensors, display openings, or other sensitive areas.
For example, a healthcare professional may disinfect the patient chair and frequently touched control surfaces between appointments using an approved product. However, spraying disinfectant directly into the equipment’s airflow sensor or electronic control panel could damage the system.
Cleaning schedules should be clearly defined so that staff understand which components require cleaning between patients and which require more extensive routine maintenance.
Maintaining body plethysmography equipment
Body plethysmography systems require additional attention because they include a sealed chamber, pressure sensors, valves, tubing, and communication components. The chamber must remain sufficiently airtight for the equipment to obtain reliable pressure measurements.
Routine maintenance may involve:
- Inspecting chamber seals and door closures.
- Checking the condition of the chamber window and internal surfaces.
- Confirming that pressure connections and tubing are secure.
- Checking the operation of the mouthpiece and breathing valves.
- Inspecting internal components for moisture or contamination.
- Confirming that the chamber door opens and closes correctly.
- Checking the operation of communication and emergency-release mechanisms.
A leak in the chamber or a damaged pressure connection may affect lung volume measurements. The equipment should therefore undergo the manufacturer’s prescribed checks, and any suspected malfunction should be investigated before clinical use.
Patient comfort is also important. The chamber should be clean, appropriately ventilated between patients according to facility procedures, and maintained in a condition that allows patients to enter, sit, and exit safely.
Maintaining gas analyzers and DLCO components
PFT systems that perform DLCO testing contain additional components used to deliver and analyze test gases. These may include gas cylinders, regulators, valves, sampling lines, and gas analyzers.
The facility should inspect gas connections for damage or leakage and ensure that the correct test gas mixture is available. Gas cylinders must be stored and handled according to applicable safety requirements, and regulators should be used as specified by the manufacturer.
Gas analyzers may require routine calibration or verification using appropriate reference gases. Their performance should be checked according to the manufacturer’s maintenance schedule and relevant laboratory standards.
For example, if a gas analyzer produces an incorrect carbon monoxide concentration reading, the calculated DLCO may be unreliable. Routine checks help identify this problem before it affects patient results.
Preventive maintenance and equipment servicing
Preventive maintenance involves scheduled inspection and servicing intended to identify potential problems before they cause equipment failure. It may include cleaning internal components, inspecting electrical connections, replacing worn parts, checking sensors, and updating software.
The maintenance schedule should be based on manufacturer recommendations, equipment usage, and the facility’s quality-assurance policy. A heavily used pulmonary function testing system may require more frequent inspection than a device used only occasionally.
Qualified technicians should perform repairs and technical adjustments that are outside the operator’s training. After major servicing, the equipment should undergo the required calibration verification and performance checks before being returned to clinical use.
A facility should also have a plan for responding to equipment breakdown. This may involve access to a backup spirometer, arrangements with a nearby respiratory laboratory, or a service agreement that provides timely technical assistance.
Cost and Technical Support
The cost of a PFT machine is an important consideration when planning to establish or expand pulmonary function testing services. However, the purchase price alone does not represent the total financial commitment. Facilities must also consider accessories, disposable supplies, calibration equipment, software, staff training, maintenance, repairs, and technical support.
The most appropriate equipment is not necessarily the least expensive or the most technologically advanced. It is the system that provides the required clinical capabilities, delivers reliable measurements, and can be maintained within the facility’s available budget.
Factors that influence PFT machine cost
The price of pulmonary function testing equipment varies considerably according to its design, capabilities, manufacturer, and intended clinical setting.
Important cost factors include:
- Type of equipment: Basic spirometers generally cost less than comprehensive pulmonary function testing systems. Equipment that includes body plethysmography and DLCO testing requires additional sensors, chambers, gas analysis components, and software.
- Measurement capabilities: A machine that performs only spirometry has fewer components than a system capable of measuring airflow, lung volumes, diffusion capacity, and other respiratory parameters.
- Technology and automation: Advanced software, automatic quality assessment, touchscreen controls, integrated reporting, and electronic medical record compatibility may increase the purchase price.
- Manufacturer and brand: Established manufacturers may charge more because of their product design, service infrastructure, warranty arrangements, and availability of accessories.
- New or refurbished condition: Refurbished equipment may have a lower initial price, but buyers should confirm its service history, calibration status, remaining useful life, and availability of replacement parts.
- Included accessories: The price may or may not include calibration syringes, filters, mouthpieces, tubing, software licenses, computers, printers, and other necessary components.
For example, a small clinic that primarily performs spirometry may find a portable spirometer more practical than purchasing a complete pulmonary function laboratory system. A specialist respiratory center that routinely assesses restrictive lung disease, emphysema, and unexplained breathlessness may require the additional capabilities of a full testing system despite its higher initial cost.
Understanding the total cost of ownership
The total cost of ownership includes the expenses associated with purchasing, operating, maintaining, and eventually replacing the equipment. A device with a low purchase price may become expensive to operate if it requires costly disposable components or frequent technical servicing.
Common ongoing expenses include:
- Disposable mouthpieces and bacterial or viral filters.
- Replacement flow sensors and tubing.
- Calibration syringes and verification accessories.
- Gas cylinders and gas analyzer supplies for DLCO testing.
- Software subscriptions, upgrades, and licensing.
- Preventive maintenance and technical servicing.
- Repairs and replacement parts.
- Staff training and competency assessments.
- Equipment transportation, installation, and setup.
Facilities should estimate the expected number of tests performed each month and calculate the approximate cost per examination. This helps determine whether the selected equipment is financially sustainable.
For example, a clinic that performs a high volume of spirometry may need to consider the cumulative cost of disposable filters and mouthpieces over a year. A specialist laboratory must also account for gas supplies, maintenance of its body plethysmography system, and servicing of its gas analyzers.
New, refurbished, and portable equipment options
Healthcare facilities may choose between purchasing new equipment, acquiring refurbished systems, or selecting portable devices according to their clinical requirements and budget.
New equipment generally provides access to the manufacturer’s current product specifications, warranty arrangements, and installation support. It may also include updated software and a longer period of expected service availability.
Refurbished equipment can offer cost savings, particularly for facilities that need advanced testing capabilities but cannot afford a new system. However, the buyer should verify that the equipment has undergone appropriate servicing, calibration, and performance testing. It is also important to confirm that software support and replacement components remain available.
Portable spirometers may be appropriate for smaller clinics, outpatient settings, community screening, and selected bedside assessments. Their portability makes them convenient, but they generally do not replace a complete pulmonary function testing system when detailed lung volume and DLCO measurements are required.
Evaluating technical support and manufacturer services
Technical support is an important consideration because pulmonary function testing equipment contains sensors, software, and other components that may require specialized maintenance. If the machine develops a fault, delayed repairs can interrupt respiratory assessments and affect patient care.
Before purchasing equipment, healthcare facilities should assess the manufacturer’s or supplier’s ability to provide:
- Installation and initial setup.
- Operator training and technical guidance.
- Routine servicing and preventive maintenance.
- Calibration and performance verification support.
- Repairs and replacement parts.
- Software updates and troubleshooting.
- Warranty coverage and post-warranty service.
- Clear instructions for reporting equipment faults.
The availability of local technical support is particularly important when equipment is purchased from an overseas manufacturer. Facilities should establish whether a trained service representative is available within a reasonable distance, how quickly replacement parts can be obtained, and whether remote technical assistance is offered.
For example, a hospital may purchase an advanced PFT system from an international supplier. If a sensor fails and replacement parts must be imported without an established service arrangement, the laboratory may be unable to perform certain tests for an extended period. Evaluating technical support before purchase helps reduce this risk.
Staff training and ongoing technical competency
The performance of a PFT machine depends partly on the knowledge and skills of the professionals operating it. Staff must understand how to prepare the equipment, perform quality checks, guide patients through breathing maneuvers, recognize technical errors, and respond to equipment warnings.
Training should cover the equipment’s operating procedures, infection prevention requirements, calibration verification, routine maintenance, test quality assessment, and basic troubleshooting. Personnel involved in interpreting results also need appropriate knowledge of pulmonary physiology and current interpretive standards.
Training should not be limited to the initial installation period. Refresher sessions and competency assessments help ensure that staff continue to use the equipment correctly, particularly when software is updated or new testing modules are introduced.
Making a practical purchasing decision
Before purchasing a PFT machine, healthcare facilities should compare available models against their clinical needs, budget, and ability to maintain the equipment. A structured evaluation helps prevent the purchase of a system that is either inadequate for the required services or unnecessarily complex for the facility’s workload.
Important questions include:
- Which pulmonary function tests must the equipment perform?
- Is basic spirometry sufficient, or are lung volume and DLCO measurements required?
- Does the machine meet relevant technical accuracy standards?
- Are calibration and quality-control procedures clearly documented?
- Are compatible mouthpieces, filters, and replacement parts readily available?
- Does the software support appropriate reference equations and reporting?
- Can the system integrate with existing patient records?
- Is staff training included in the purchase arrangement?
- What warranty and maintenance services are provided?
- Is technical support available when repairs are required?
- What are the estimated operating and maintenance costs over the equipment’s expected working life?
A facility should also request a demonstration where possible and evaluate how easily staff can perform routine testing using the proposed system. Comparing the performance, service arrangements, and total operating costs of different models provides a stronger basis for decision-making than relying on the purchase price alone.
Selecting suitable equipment and maintaining it through consistent quality-control procedures are essential to reliable pulmonary function testing. A well-chosen PFT machine should meet the facility’s clinical requirements, provide accurate and reproducible measurements, and remain practical to operate over time. Regular calibration verification, cleaning, preventive maintenance, staff training, and access to technical support help preserve equipment performance and ensure that the results remain useful for respiratory assessment and patient care.

Conclusion
A PFT machine is an important diagnostic tool in respiratory medicine because it provides objective measurements of how effectively the lungs function. By assessing airflow, lung volumes, and gas exchange, pulmonary function testing helps healthcare professionals investigate breathing problems, identify patterns of respiratory impairment, and evaluate conditions such as asthma, chronic obstructive pulmonary disease (COPD), emphysema, and pulmonary fibrosis. Different types of equipment, including spirometers, portable PFT systems, and body plethysmography machines, support these assessments by measuring specific aspects of respiratory performance.
Understanding the different pulmonary function tests is essential for appreciating the information they provide. Spirometry evaluates airflow and measurements such as forced expiratory volume in one second (FEV1) and forced vital capacity (FVC), while lung volume testing determines how much air the lungs can contain. DLCO testing provides additional insight into the efficiency of gas transfer between the lungs and bloodstream. When these measurements are interpreted together with patient symptoms, medical history, physical examination findings, and other investigations, they help establish a clearer understanding of respiratory health and guide appropriate clinical decisions.
Reliable results also depend on more than the capabilities of the equipment. Proper patient preparation, correct breathing techniques, appropriate mouthpiece use, infection prevention, and adherence to standardized testing procedures all contribute to accurate measurements. Regular calibration, quality-control checks, cleaning, and preventive maintenance are equally important for ensuring that a PFT machine continues to operate safely and consistently. Healthcare professionals must also recognize that test results require careful interpretation and should not be used in isolation to establish a diagnosis.
For nurses and other healthcare professionals, knowledge of pulmonary function testing supports effective patient education, preparation, monitoring, and collaboration with respiratory specialists. Understanding what each test measures and how its findings contribute to respiratory assessment makes it easier to support patients throughout the testing process and communicate relevant observations to the clinical team. With appropriate equipment, skilled operation, and accurate interpretation, pulmonary function testing remains a valuable part of diagnosing lung conditions, monitoring disease progression, and evaluating treatment effectiveness.
Frequently Asked Questions
What Does a PFT Machine Do?
A PFT machine measures how well the lungs work by assessing airflow, lung volumes, and the ability of the lungs to transfer gases into the bloodstream. It helps identify and monitor respiratory conditions such as asthma, COPD, and pulmonary fibrosis.
How Much Does a PFT Machine Cost?
The cost depends on the equipment type, features, and manufacturer. Basic portable spirometers may cost a few hundred to several thousand US dollars, while advanced pulmonary function testing systems with lung volume and DLCO capabilities can cost tens of thousands of dollars or more.
How Much Does a PFT Cost?
The cost of a pulmonary function test varies depending on the tests performed, healthcare facility, location, and insurance coverage. In the United States, basic spirometry may cost approximately $30–$150, while comprehensive pulmonary function testing can range from about $200 to over $1,000.
Can a PFT Show Heart Problems?
No. A PFT primarily evaluates lung function and cannot directly diagnose heart conditions. However, abnormal results may indicate respiratory problems contributing to symptoms such as shortness of breath. Because heart and lung conditions can cause similar symptoms, healthcare providers may recommend additional investigations, such as an electrocardiogram (ECG), echocardiogram, or cardiac stress test, to assess heart function.